Pharmacological Management of Gambling Disorder: A Systematic Review and Network Meta-Analysis

Konstantinos Ioannidis[a,b*], Cinzia Del Giovane[c], Charidimos Tzagarakis[d], Jeremy E Solly[b,e], Samuel J. Westwood[f#], Valeria Parlatini[f#], Henrietta Bowden-Jones[h], Jon E Grant[i], Samuele Cortese[j], Samuel R Chamberlain[a]

[a] Department of Psychiatry, Faculty of Medicine, University of Southampton, UK; and Southern Health NHS Foundation Trust, Southampton, UK

[b] Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK

[c] Department of Medical and Surgical Sciences for Children and Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy and Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

[d] Organization Against Drugs (OKANA), Athens, Greece and Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States

[e] Department of Psychiatry, University of Cambridge, UK

[f] Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

[g] Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK and Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

PHARMACOLOGICAL MANAGEMENT OF GAMBLING DISORDER: A NETWORK META-ANALYSIS

[h] National Problem Gambling Clinic & National Centre for Gaming Disorders, London, UK; and Department of Psychiatry, University of Cambridge, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.

[i] Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA

[j] Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK; Solent NHS Trust, Southampton, UK; DiMePRe-J-Department of Precision and Rigenerative Medicine-Jonic Area, University of Bari "Aldo Moro", Bari, Italy; Department of Child and Adolescent Psychiatry, New York University Grossman School of Medicine, New York

* Corresponding author; Email: konstantinosioannidis8@gmail.com

[#] equally contributed

Word count: 4646

PHARMACOLOGICAL MANAGEMENT OF GAMBLING DISORDER: A NETWORK META-ANALYSIS

ABSTRACT

Background: Guidelines remain unclear on which medications for gambling disorder are to be preferred in terms of efficacy and tolerability.

Aims: To compare pharmacological treatments for gambling disorder with each other and placebo on efficacy and tolerability, using network meta-analysis (NMA).

Methods: We searched a broad range of databases for double-blind randomized controlled trials (RCTs) of medications for gambling disorder. Outcomes were gambling symptom severity and quality of life (for efficacy); as well as tolerability. Confidence in the network estimates was assessed using the CINeMA framework.

Results: We included 21 RCTs in the systematic review and 15 RCTs (n=940 participants) in the NMA. Compared with placebo, high confidence evidence indicated that nalmefene [Standardized Mean Difference (SMD): -0.87; 95% confidence interval (CI: -1.33,-0.41)] reduced gambling severity, followed by naltrexone [-0.43; -0.83,-0.02)]. Nalmefene [Odds Ratio (OR): 7.55; 95%CI: 2.24-24.41] and naltrexone (7.82; 1.26-48.70) had significantly higher dropout (lower tolerability) compared with placebo. As compared with placebo, naltrexone (SMD: -0.49; 95%CI: -0.81,-0.18) and nalmefene (-0.36; -0.72,-0.01) were beneficial in terms of quality of life.

Conclusions: Nalmefene and naltrexone currently have the most supportive evidence for the pharmacological treatment of gambling disorder. Further clinical trials are needed, as well as analysis of individual participant data, to strengthen and broaden the evidence base, and to help tailor treatments at the individual patient level.

Key words: Gambling; Network meta-analysis; Pharmacotherapy; treatment

INTRODUCTION

Gambling disorder is a complex behavioural addiction, which affects individuals and those around them and has substantial public health implications worldwide (1). It is characterized by persistent and recurrent gambling leading to negative consequences, including e.g. interpersonal conflict, serious financial problems, homelessness, mortgage foreclosure, and elevated risk of suicide (2,3). Gambling disorder is currently classified as a behavioural addiction in the International classification of Disease 11th Edition (ICD-11) (4) and as a Substance-Related and Addictive Disorder in the Diagnostic and Statistical Manual Version 5 (DSM-5) (5).

Psychological interventions (i.e., gambling focused cognitive-behavioural therapy [CBT], in its many variants) are widely used to treat gambling disorder (3). However, there is no consensus about gold standard treatments. Some international guidelines suggest, further to CBT, pharmacological options (specifically, naltrexone) for treatment-resistant gambling disorder (6) or adjunct pharmacology to talking therapies or as monotherapy (7). Also, those guidelines recommend against the use of antidepressants as monotherapy for gambling disorder, unless there is comorbid depression or anxiety.

There have been previous attempts to pool evidence from many studies on the pharmacological management of gambling disorder. A pairwise meta-analysis including 34 studies (open label, non-randomized and randomized control trials [RCTs], with or without concomitant psychological interventions), showed large effects for pharmacological treatments overall (Hedge's g=1.35 in global severity of gambling; medium effect size, g=0.41 when including RCTs only) (8). Notably, this prior review was not designed to compare different compounds, and moreover, did not find differences in effects between classes of medication (8).

A recent Cochrane systematic review and pairwise meta-analysis of the pharmacological interventions of disordered and problem gambling (9) used a major-category examination approach (e.g. "antidepressants", "opioid-antagonists") across seventeen studies (n=1193), and found evidence that antidepressants and mood stabilizers were no better than placebo in treating gambling symptoms. Opioid antagonists and atypical antipsychotics were reported as being beneficial in treating gambling symptoms. However, this meta-analysis

only considered direct (head-to-head) comparisons, and this limited the number of comparisons included due to the paucity of head-to-head studies for gambling disorder (9).

Thus, many important questions remain unanswered, including: 1) which individual compounds (even from those within the same class, e.g. opioid receptor antagonists) should be chosen as first-line treatments for gambling disorder; 2) which are best tolerated medications when compared to each other; and 3) which medications have the strongest impact on quality of life.

Network meta-analysis (NMA) can address these crucial gaps in the field, by integrating, under certain methodological assumptions, multiple direct and indirect treatment comparisons (10), which can then be used to compare the effects of several interventions simultaneously (11). One of the advantages of NMAs, is that by adding indirect evidence, they increase the precision of an effect size estimate, even when there is direct evidence for that specific comparison (10). Notably, while the useful insights produced by NMAs are well established, many NMAs are commissioned by industry, they are not pre-registered, and never get published to allow for an equitable dissemination of knowledge and public health benefits (12). At a time when the UK National Institute for Health and Care Excellence (NICE) is developing initial clinical guidelines for gambling disorder (13), an NMA is urgently needed to allow for a thorough and up-to-date examination of evidence supporting pharmacological treatment(s) for gambling disorder. Such work is also likely to directly inform other international guidelines (whether new or updated) in the future. Therefore, we conducted the first NMA to compare the effects of pharmacological treatments on symptoms and quality of life, in the management of gambling disorder – as well as the relative tolerability of such treatments.

METHODS

This study followed the PRISMA-NMA guidelines (14) and its protocol was pre-registered and published online on the PROSPERO International prospective register of systematic reviews [Available from: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=329520]. Additional methodological details are presented in the supplement (Supplement §S1). The PRISMA-NMA checklist is shown in the supplement (Supplement §S2).

PHARMACOLOGICAL MANAGEMENT OF GAMBLING DISORDER: A NETWORK META-ANALYSIS

Search strategy

The search strategy was determined by consensus amongst the co-authors, with further expert refinement from Systematic Review Solutions Ltd. (SRS), an independent health research service company specialising in evidence-based medicine methods and meta-research training, production of systematic reviews and Health Technology Assessment reports, and development of clinical practice guidelines. SRS conducted the initial literature scan and supplied detailed results to the study team, as per previously published NMAs. The initial search was conducted in July of 2022, and author KI repeated the PubMed search on the 23rd of September 2023 to ensure no new studies were identified (this did not identify any new studies since the original search). The search strings and full list of clinical registers in which the literature search was conducted are available in the supplement (Supplement §S3).

Identification and selection of studies

First, two authors (JES, CT) independently screened titles and abstracts of all non-duplicated papers and agreed on a final list of studies that proceeded to full-text screening. A manual search of references was performed at that stage for identification of further studies. Then, these two authors independently assessed the eligibility of these studies for the systematic review and NMA. Any discrepancy between the two authors was resolved by research team meetings to achieve consensus.

Eligibility criteria

We included RCTs comparing an active medication vs. placebo, or active medications with each other, for the treatment of Gambling Disorder/Pathological Gambling. Trials with a cross-over design were included if data from the pre cross-over phase were available, to avoid carry-over effects (15). We included only studies of adults (>18yrs) with a primary DSM (III onwards) or ICD (9 onwards) diagnosis of Gambling Disorder/Pathological Gambling. Included studies had to be: a) published in scholarly peer-reviewed journals since 1987; and b) be written in English or have available an English translation as part of their publication.

We excluded studies that a) were not randomized trials and/or b) did not assess the pharmacological management of gambling disorder. For the NMA, we additionally excluded studies which: c) had insufficient

data for NMA, and d) specifically included a primary psychiatric condition in the whole sample, other than gambling as part of inclusion criteria.

Data extraction and outcomes

Two authors (JES, CT) independently extracted information from the studies selected for the systematic review. Any discrepancy was resolved by a third author (KI). Data extracted from all studies in the systemic review included: demographic (mean age, % male), study design (sample size, number of arms, parallel or cross-over design, pragmatic design, single or multicentre, placebo control, the role of sponsorship), medicinal (dose used, dosing scheme and route of administration), clinical (diagnostic criteria for gambling disorder, presence of co-morbidities) characteristics. For the NMA we also extracted primary and secondary efficacy outcomes (mean, standard deviation).

The primary efficacy outcome was gambling symptom severity measured by well-established relevant and validated instruments, namely the Yale-Brown Obsessive Compulsive Scale adapted for Pathological Gambling (PG-YBOCS) (16), the Gambling Symptom Assessment Scale (G-SAS) (17), and the Clinical Global Impression-Improvement scale (CGI-I) (18). If a study reported results from multiple scales, we used the following hierarchy in the choice of the scale: PG-YBOCS as first preference; G-SAS as next preference, CGI-I as third preference. This was done to prioritize structured clinical instruments against unstructured or self-report instruments. The primary tolerability outcome was defined as the proportion of patients who exited a given study due to side-effects. The secondary efficacy outcome was the improvement in quality of life and functioning as measured by validated instruments including but not limited to the Sheehan Disability Scale (SDS) (19) and other Quality of life metrics. Where outcome data or any relevant information were missing, the corresponding authors of the individual papers were contacted with a request to provide unpublished data/information.

Data synthesis

We calculated the standardized mean differences (SMD) using Hedges' g to measure the efficacy outcomes, because different scales were used to assess the same outcome. The measure of effect for tolerability was the dropout rate due to medication side effects, expressed as odds ratio (OR). Multi-arm trials examining dosing

schemes were collapsed into two arms (active treatment vs. placebo). First, we conducted conventional pairwise meta-analyses with a random-effects model for all outcomes and treatment comparisons with at least two studies (20), followed by frequentist NMA for all outcomes using random-effects models. We also performed a sensitivity analysis by conducting NMA for gambling severity, by analysing each scale of gambling severity separately, and restricting the analysis to mean difference (MD) only. We evaluated the assumption of transitivity within NMA by assessing the similarities of the distributions of the potential effect modifiers, such as study and patient-level covariates, across pairwise comparisons (21). All results were reported as treatment effects with their 95% confidence intervals (95%CIs). In standard pairwise meta-analysis, we assessed the heterogeneity within each comparison visually by considering the forest plot, and quantitatively with the I^2 statistic and the tau^2 (20). In NMA, we assumed a common parameter for heterogeneity across comparisons in each network and we estimated the heterogeneity standard deviation tau for each outcome τ (22). Statistical incoherence was evaluated globally by using the design-by-treatment approach and locally by using both the node-splitting approach and the loop-specific approach (23). Surface Under the Cumulative RAnking (SUCRA) (24) curves were used to measure, for any outcome, the probability for each treatment to be the best among all treatments included in the network. Additionally, we calculated other available ranking metrics, i.e. mean rank and the probability to be the best treatment (22,24). We used STATA®/IC 18.1 (StataCorp LLC, College Station, TX, USA) to perform all analyses.

Study risk of bias assessment and confidence in Network Meta-Analysis estimates (CINeMA)

We used the Confidence in Network Meta-Analysis (CINeMA) framework to assess the confidence in the estimates obtained from the NMA; this was done separately for gambling severity, tolerability and quality of life. The framework considers six domains: within-study bias, reporting bias, indirectness, imprecision, heterogeneity, and incoherence (25). For within-study bias, each individual RCT included in our Network Meta-Analysis was assessed using the Cochrane Risk of Bias tool version 2 (RoB-2), as recommended in The Cochrane Handbook of Systematic Reviews of Interventions (26). The tool includes five domains on different sources of bias. For RCTs (including cross-over trials), these include: 1) bias arising from the randomisation process; 2) bias due to deviations from intended interventions; 3) bias due to missing outcome data; 4) bias in

measurement of the outcome; and 5) bias in selection of the reported result. More information about how CINeMA was implemented is presented in the supplement (Supplement §S4).

RESULTS

The initial search yielded 4,095 references from databases and 70 hits from clinical registers. CT and JES independently screened all eligible papers and agreed on a final set of 21 eligible studies for inclusion in the systematic review. Inter-rater reliability, determined using the Finn coefficient, was 0.863 (good), (p<0.001, calculated using R [package "irr"](27)) and all disagreements were resolved by consensus. Six of these studies were excluded from the NMA either due to insufficient data (four studies), or the inclusion of a primary psychiatric co-concurrent condition in the whole sample (two studies) (28,29), which we deemed violated the NMA transitivity assumption. Each of the 15 RCTs included in the NMA contributed to one pairwise comparison, totalling 15 pairwise comparisons across studies (15 for gambling severity, 12 for tolerability, 8 for quality of life). The total number of participants was 940; they were mostly males (~59%), and their age ranged from 27.9 to 50.6yrs (Mean=45.6; SD=4.21). Full details about the search results are presented in the PRISMA flowchart (Figure 1). Full characteristics of the studies, including RoB 2 and ORBIT assignments are presented in the supplement (Supplement §S5).

Figure 1 – PRISMA Flowchart of studies identification

Legend: *PRISMA flowchart*

Comparisons included in the NMA comprised eight different medications: three opioid receptor antagonists, (naltrexone, nalmefene, naloxone); two selective serotonin reuptake inhibitors (SSRIs - paroxetine and fluvoxamine); one mood stabilizer/antiepileptic (topiramate); one norepinephrine–dopamine reuptake inhibitor (NDRI, bupropion); and one antipsychotic (olanzapine). Six more medications were identified in the overall systematic review, but were not included in the NMA: lithium, sertraline, clomipramine, baclofen, acamprosate and n-acetyl-cysteine (NAC). These trials are considered further in the discussion, but did not have enough data to be included in the NMA or met other exclusion criteria. Examining the characteristics of included NMA studies we did not identify any evidence that the transitivity assumption did not hold.

Results from the conventional pairwise meta-analysis for each outcome and within each treatment comparison are showed in the forest plots in the supplement (Supplement §S6). Figure 2 shows the network plots for efficacy on gambling severity, tolerability and efficacy on quality of life.

Figure 2 – Network plots

Legend: *Network plots for: (A) – Efficacy on gambling severity (15 studies); (B) tolerability (12 studies); (C) Efficacy on quality of life (8 studies). Size of nodes represents the number of studies in each comparison. Width of the edges represents the number of participants in each comparison. Colour of nodes is according to Rob 2.*

Forest plots of NMA results for gambling severity, tolerability, and quality of life showing the network estimates for each treatment versus placebo are presented in Figure 3. The results of the NMA for efficacy on gambling severity and tolerability for all possible comparisons are shown in Table 1. The results of the NMA for quality of life are presented in Table 2. In terms of gambling severity, among eight active drugs and placebo, nalmefene [SMD: -0.87; 95% confidence interval (CI: -1.33, -0.41)] was associated with higher efficacy compared with placebo, followed by naltrexone [SMD: -0.43; 95%CI: -0.83, -0.02)]. Between medication treatments, we identified a superiority of nalmefene over naloxone (SMD 1.02 (95%CI: 0.22,1.82)). In terms of tolerability, nalmefene (OR 0.13 (95%CI: 0.04, 0.45)) and naltrexone (OR 0.13 (95%CI: 0.02, 0.80)) were found to be the least tolerated (i.e., having the highest dropout risk due to side effects) as compared with placebo. We did not find any significant difference between treatments. Naltrexone (SMD 0.49 (95%CI: 0.18, 0.81)) and nalmefene (SMD 0.36 (0.01, 0.72) were associated with higher quality of life compared with placebo. Among medication treatments, we identified a superiority of naltrexone over

naloxone (SMD -0.61 (95%CI: -1.08, -0.14)). Main NMA results from sensitivity analyses of gambling severity are presented in the supplement (Supplement §S7).

Figure 3 – Forest plots of NMA results for gambling severity, tolerability and quality of life

TOLERABILITY

Treatment Effect		OR with 95%CI	SUCRA	CINeMA
Olanzapine		2.32 (0.45,11.80)	63.4	Low
Topiramate		2.71 (0.38,19.55)	57.3	Moderate
Paroxetine		3.59 (0.64,20.12)	50.7	Moderate
Fluvoxamine		4.09 (0.14,120.69)	47.3	Low
Bupropion		5.87 (0.80,42.90)	36.7	Moderate
Nalmefene		7.55 (2.24,25.41)	27.1	High
Naltrexone		7.82 (1.26,48.70)	26.5	Moderate

.1 .7 22 122

Favours Treatment   Favours Placebo

QUALITY OF LIFE

Treatment Effect	SMD with 95%CI	SUCRA	CINeMA
Naltrexone	-0.49 (-0.81,-0.18)	63.4	Very Low
Topiramate	-0.43 (-0.88,0.01)	57.3	Moderate
Nalmefene	-0.36 (-0.72,-0.01)	50.7	Low
Paroxetine	-0.09 (-0.56,0.37)	47.3	Low
Bupropion	0.07 (-0.62,0.75)	36.7	Low
Naloxone	0.12 (-0.23,0.47)	27.1	Low

-.9 -.5   0   .4 .8

Favours Treatment   Favours Placebo

Legend – *Forest plots of NMA results; SUCRA = surface under the cumulative ranking curve; CINeMA = Confidence in network meta-analysis*

Table 1 - NMA results for all possible comparisons for gambling severity (lower triangle) and tolerability (upper triangle)

placebo	0.43 (0.08,2.20)	**0.13 (0.02,0.80)**	NA	0.37 (0.05,2.66)	0.28 (0.05,1.56)	**0.13 (0.04,0.45)**	0.24 (0.01,7.21)	0.17 (0.02,1.24)
0.23 (-0.41,0.87)	olanzapine	0.38 (0.03,5.81)	NA	0.85 (0.07,11.05)	0.64 (0.06,6.91)	0.31 (0.04,2.34)	0.57 (0.01,24.21)	0.39 (0.03,5.15)
0.43 (0.02,0.83)	0.20 (-0.56,0.95)	naltrexone	NA	2.23 (0.12,42.09)	1.68 (0.10,26.99)	0.80 (0.07,9.67)	1.48 (0.03,82.52)	1.33 (0.34,5.27)

-0.15 (-0.80,0.51)	-0.38 (-1.29,0.54)	-0.57 (-1.35,0.20)	**naloxone**	NA	NA	NA	NA	NA
0.33 (-0.26,0.92)	0.10 (-0.77,0.97)	-0.10 (-0.82,0.62)	0.47 (-0.41,1.36)	**topiramate**	0.76 (0.05,10.39)	0.36 (0.04,3.65)	0.66 (0.01,33.36)	0.67 (0.03,18.09)
0.17 (-0.38,0.71)	-0.06 (-0.90,0.77)	-0.26 (-0.94,0.42)	0.31 (-0.54,1.16)	-0.16 (-0.97,0.64)	**paroxetine**	0.48 (0.06,3.92)	0.88 (0.02,39.15)	0.61 (0.04,8.49)
0.87 (0.41,1.33)	0.64 (-0.14,1.42)	0.45 (-0.17,1.06)	**1.02 (0.22,1.82)**	0.54 (-0.20,1.29)	0.70 (-0.01,1.42)	**nalmefene**	1.84 (0.05,67.22)	1.28 (0.13,13.20)
0.15 (-1.08,1.37)	-0.08 (-1.46,1.30)	-0.28 (-1.57,1.01)	0.29 (-1.10,1.68)	-0.18 (-1.54,1.18)	-0.02 (-1.36,1.32)	-0.72 (-2.03,0.58)	**fluvoxamine**	0.70 (0.01,35.28)
0.26 (-0.39,0.91)	0.03 (-0.88,0.94)	-0.17 (-0.81,0.48)	0.40 (-0.52,1.33)	-0.07 (-0.95,0.81)	0.09 (-0.76,0.94)	-0.61 (-1.41,0.18)	0.11 (-1.28,1.50)	**Bupropion**

Legend: *Lower triangle: SMD and 95%CI in brackets for efficacy on gambling severity; read from left to right, positive scores favour treatment on the right (better treatment effect). Upper triangle: tolerability assessed with ORs from drop outs due to side effects and relative 95%CI; read from right to left; ORs below 1 favour treatment on the left (better tolerated). Values highlighted in bold are significant results. Note: Alho et al. 2022 (naloxone vs placebo) was excluded from tolerability analysis due to non-events in both treatment arms.*

Table 2 - NMA results for all possible comparisons for quality of life

topiramate			
-0.43 (-0.88,0.01)	**placebo**		
-0.34 (-0.99,0.30)	0.09 (-0.37,0.56)	**paroxetine**	
0.06 (-0.49,0.60)	**0.49 (0.18,0.81)**	0.40 (-0.16,0.96)	**naltrexone**

-0.55	-0.12	-0.21	**-0.61**	**naloxone**		
(-1.12,0.01)	(-0.47,0.23)	(-0.79,0.37)	**(-1.08,-0.14)**			
-0.07	**0.36**	0.27	-0.13	0.48	**nalmefene**	
(-0.64,0.50)	**(0.01,0.72)**	(-0.32,0.86)	(-0.61,0.35)	(-0.02,0.98)		
-0.50	-0.07	-0.16	-0.56	0.05	-0.43	**bupropion**
(-1.32,0.32)	(-0.75,0.62)	(-0.99,0.67)	(-1.31,0.20)	(-0.72,0.82)	(-1.20,0.34)	

Legend: *Lower triangle: SMD and 95%CI in brackets for quality of life; read from left to right, positive scores favour treatment on the right (better treatment effect). Values highlighted in bold are significant results.*

Heterogeneity measures (i.e., common standard deviation heterogeneity estimates) and results from incoherence assessment for all outcomes are presented in in the supplement (Supplement §S8).

Treatment ranking measures based on NMA results are presented in detail in the supplement for primary outcomes (Supplement §S9). Sensitivity analysis for low risk of bias studies was not possible due to all available studies having scored "some concerns" or above.

Confidence in network meta-analysis estimates based on CINeMA

The confidence in the NMA estimates ranged between very low to high. Moderate and high confidence was assigned to most of the comparisons versus placebo. In particular, we were highly confident that nalmefene was the most effective and least tolerated treatment when compared to placebo. The main reasons for downgrading confidence were within-study-bias, imprecision and heterogeneity. Full CINeMA assessment for gambling severity, tolerability and quality of life are presented in the supplement (Supplement §S10).

DISCUSSION

This is the first NMA of RCTs for the pharmacological management of gambling disorder. We found high confidence evidence indicating that nalmefene was the most effective treatment in reducing gambling symptom severity. The other opioid antagonist often used in clinical practice, naltrexone, had moderate confidence evidence of being the second most efficacious treatment; it also had the highest probability of improving quality of life (very low confidence). Both these treatments were associated with significantly

higher dropout, due to side effects, than placebo, with confidence from moderate (naltrexone) to high (nalmefene). Both nalmefene (in gambling severity, moderate confidence) and naltrexone (in quality of life, low confidence) showed superiority against naloxone in indirect comparisons. We did not find any other significant differences among medications. Naloxone did not differentiate from placebo in the one available study (30). Notably, naloxone is an opioid antagonist but has a very short duration of effect (short half-life) (31), so lack of efficacy is perhaps unsurprising. Overall, these results provide useful insights that can support clinical decision-making around the pharmacological management of gambling. There are differences between opioid receptor antagonists in how they bind to brain receptors. For example, naltrexone has a preference for mu opioid receptors (MOR) and binds to a lesser extend to kappa opioid receptors (KOR), while nalmefene binds with similar strength to MOR and KOR (31). Such differences could theoretically influence treatment effects and tolerability profiles, but ultimately, both medications are thought to dampen dopamine neurotransmission in the nucleus accumbens and associated motivational neurocircuitry, reducing gambling excitement and craving (32).

This NMA provides other interesting insights. Contrary to a recent Cochrane review (9), this NMA showed that olanzapine was not statistically better than placebo in terms of primary or secondary efficacy outcomes. Due to combining direct and indirect evidence, as well as head-to-head comparisons, an NMA analysis may provide more accurate and complete results as compared to a conventional pairwise meta-analysis. Our NMA indicated that olanzapine is a less preferred treatment option for gambling disorder than previously considered, due to lack of efficacy. We found low confidence evidence indicating that olanzapine was the most well-tolerated among treatments. This is clinically surprising given its established and notable side effect profile more widely in the psychiatric literature (33). However, considering the lack of evidence of its efficacy, a preferable tolerability profile becomes less important.

Furthermore, we observed moderate confidence evidence that topiramate was not different from placebo in NMA on any of the primary or secondary outcomes (34,35). Topiramate has a complex pharmacology and many cellular targets have been implicated in its therapeutic mechanism. It has been used in other areas of addiction psychiatry, e.g., alcohol use disorder (36). However the mechanism of action and supporting

evidence is still unclear and might merit further evaluation in clinical trials before being dismissed as a treatment option for gambling disorder.

Consideration of studies identified in the systematic review but not included in NMA

Other treatments that have been used in addiction psychiatry have attracted interest for RCTs in gambling disorder, such as baclofen and acamprosate (37). Those studies were negative and their reports did not provide enough data for them to be included in the current NMA. This was also the case for sertraline (38); interestingly the sertraline RCT was characterized by >70% response in both active treatment and placebo groups.

Two other studies (on lithium (28) and n-acetyl cysteine [NAC] (39), respectively) were excluded from our NMA, as their studies involved recruitment of patients required to have a particular single named disorder in addition to gambling disorder, which violated the transitivity assumption necessary for inclusion. In an RCT examining lithium monotherapy for pathological gamblers with bipolar spectrum disorders (28), lithium was beneficial in reducing both gambling symptoms and mania scores, versus placebo. Lithium would thus appear to be a potentially useful option for gambling, which is comorbid with bipolar spectrum disorders during a mood episode. However it remains to be seen whether this would also apply to gambling disorder without this comorbidity. NAC was used successfully in one open label study (40) and then one placebo-controlled RCT (41) which included participants with a primary nicotine dependence diagnosis and gambling disorder (i.e. both were mandatory). Nicotine dependence has been identified as amongst the most common mental health comorbidity in gamblers (42). While the trial at the end of treatment (12 weeks) did not show any benefit for NAC for gambling (though it did, interestingly, in terms of reducing symptoms of nicotine dependence), the 24 week follow-up indicated that those previously treated with NAC had lower gambling severity than those previously treated with placebo. NAC is very well tolerated treatment and has been successfully used in impulse control disorders (43), which share many pathophysiology characteristics with gambling disorder. Further studies are warranted to assess the efficacy of NAC in gambling disorder.

Finally, the pioneer clomipramine study (44) was an N-of-1 and was therefore excluded from NMA. Unfortunately, clomipramine has not been studied further in RCTs, despite the fact that the medication has

been proven beneficial for other disorders which share characteristics with gambling, e.g. obsessive-compulsive disorder (OCD), including its treatment resistant type (45).

Limitations

Several limitations should be considered, reflecting both limitations of the included RCTs and of our NMA. In terms of limitations of the included RCTs, 80% of them were judged of moderate quality and 20% of low quality at the RoB2, mainly due to concerns over bias in the selection of reported result, but also missing outcome data. This reflects the state of the field and the fact that gambling disorder has been relatively neglected as compared to other mental health conditions, with most studies having been completed more than a decade ago. High quality RCTs are scarce and, in our view, this highlights further the importance of this NMA analysis in guiding the design of future RCTs. Moreover, the vast majority of the samples included both genders of middle aged participants. Differential gender effects could not be examined and the results cannot be extrapolated to other age groups e.g. olden people or children and adolescents. Furthermore, while we did not measure significant heterogeneity across studies overall, there were some methodological differences among studies that need to be considered. Different dosing schemes could have accounted for some heterogeneity– for example, Kovanen et al. (46) used as required (PRN) dosing of naltrexone, as opposed to previous studies which used daily schemes with titration to a maximum tolerated dose using clinical judgement (17,47). Similarly, the two nalmefene studies used different dosing schemes (20mg/40mg vs. 25mg/50mg/100mg) (48,49), and dose can potentially influence efficiency and tolerability outcomes, including dropout rates. In terms of limitations of our NMA, due to the presence of few closed loops in our network, we were not able to assess incoherence in all areas of our network. In the loops assessed we did not find evidence of incoherence. Moreover, due to the limited number of available studies, we were not able to meaningfully perform meta-regression to assess whether duration of treatment or mode of administration or dosing moderated effects in our network. However, most of the included studies had a similar duration of treatment between 12-20 weeks and used oral treatments. Furthermore, we did not have enough data to test effect modifiers like study sponsorship, comorbid psychiatric conditions, and mean baseline severity. Finally, while NMAs, in general, do not generate randomized evidence, they do provide observational evidence and helpful insights into the clinical dilemma of choosing between pharmacological options. Therefore, while

NMA allows for indirect head-to-head comparisons, those could theoretically be estimated from real-life RCTs. In practice, though, this can be prohibitively expensive and time consuming.

Implications of the results for practice, policy, and future research

The current NMA provides the highest level of evidence synthesis to inform clinical practice as well as national and international treatment guidelines in terms of pharmacological options that should be recommended for gambling disorder. Based on the NMA findings, naltrexone and nalmefene should currently be regarded as having the best available evidence for the treatment of gambling disorder. In the context of other disorders, it has been argued that nalmefene may have advantages over naltrexone in terms of its bioavailability, ability to bind differentially to particular brain opioid receptors (stronger affinity to kappa opioid receptors, mechanistically relevant in exerting antidepressant effects, but can also alter the side effect profile (50,51)), and its apparent absence of dose-dependent liver toxicity (for discussion see (52)). However, in the absence of direct head-to-head comparisons of these two medications in gambling disorder, and rigorous health-economic evaluations, we would suggest that both are retained as key first-line pharmacological treatment options. Retaining several options may also reduce the likelihood of patients having no feasible pharmacological treatment option – such as if one medication is not available in a particular geographical area/country, or in the case of supply disruptions.

Given the limited number of treatment options identified in the current NMA, and the high public health priority of gambling disorder (3,53), further large-scale clinical trials are urgently needed in relation to these and other medications for gambling disorder. A major reason for the low yearly rate (<1/year) of pharmacological RCTs for gambling disorder over the past decade, and relatively small number of studies accrued over time, is the lack of independent research funding being made available. Therefore, we urgently call on national funding bodies to support independent clinical trials into gambling disorder. A summary of recommendations for future clinical trials for gambling disorder are made in Box 1, based on the findings of this review.

BOX 1: RECOMMENDATIONS FOR FUTURE CLINICAL TRIALS OF PHARMACOLOGICAL INTERVENTIONS FOR GAMBLING

- Full data reporting and adherence to intention to treat principles.

- Fostering wider collaborations and research design and dissemination practices to support data synthesis using individual participant data (PID) is critical
- Standardization of treatment duration and follow up
- Nalmefene and naltrexone show the best efficacy profile, however they coupled with relatively lower tolerability versus other compounds or placebo. To address tolerability issues, clinicians should initially consider doses found to be effective but not in the high range e.g. 50mg-100mg for naltrexone, 50mg or less for nalmefene. At the same time, it should be appreciated that higher doses may be needed in particular cases, such as in treatment non-response or partial response.
- Topiramate ranked relatively highly in terms of efficacy and tolerability profile, but it was not statistically better than placebo. Further studies are warranted to determine if this is an issue with statistical power.
- Due to its good tolerability profile, future studies should further examine NAC to assess its efficacy.

Data availability

The data that support the findings of this study are available upon reasonable request from the corresponding author.

Analytic code availability

Example STATA code for NMA can be found in the supplement (Supplement §S11).

Acknowledgement

We would like to thank authors of published papers included in this network meta-analysis who responded to requests for additional information to enable the meta-analysis.

Funding

This study was supported by unrestricted grant funds to Professor Chamberlain held at the University of Southampton, originating from the NHS. The funding source had no role in the design, conduct, or reporting of the study.

Declaration of interest

Professor Chamberlain is service director for the NHS Southern Gambling Service. Professor Chamberlain receives a stipend from Elsevier for journal editorial work. Professor Bowden-Jones is National Clinical Advisor on Gambling Harms in the UK, and is Director of the National Problem Gambling Clinic and the National Centre for Gaming Disorders. Professor Bowden-Jones' clinics receive funding from NHS England and CNWL NHS Trust. Professor Bowden-Jones' clinics previously received funding from GambleAware.

Cinzia del Giovane's time on the project was funded partly through the grant funding to SRC. Dr Ioannidis is clinical lead for the Southern Gambling Service and receives a stipend from Elsevier for journal editorial work. Dr. Grant has received research grants from Janssen and Biohaven Pharmaceuticals. He receives yearly compensation from Springer Publishing for acting as Editor-in-Chief of the Journal of Gambling Studies and has received royalties from Oxford University Press, American Psychiatric Publishing, Inc., Norton Press, and McGraw Hill. None of the authors have conflicts of interest in relation to the gambling or gaming industry. None of the authors accept voluntary donations from the gambling or gaming industry either personally or in terms of institutional funds held in their name.

Transparency declaration

KI as the lead author and manuscript guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as registered have been explained.

Author contributions

KI, CT, JES, SC, SRC contributed to the design of the study; CT led the initial pre-registration; CT and JES led the search and screening process; KI, CDG, SRC contributed to data collection. KI, CDG and SRC had access to the data. KI and CDG conducted the NMA analysis and take responsibility for the integrity and accuracy of the data analysis itself. SHW and VP led and equally contributed on the RoB2 scoring. All authors have intellectually contributed and reviewed the final submitted manuscript. All authors accept responsibility for the conduct of the study and its integrity.

Author details

Konstantinos Ioannidis MRCPsych, PhD, Faculty of Medicine, Department of Psychiatry, University of Southampton, UK and Southern Health NHS Foundation Trust, Southampton, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; **Cinzia Del Giovane** PhD, Department of Medical and Surgical Sciences for Children and Adults, University-Hospital of Modena and Reggio Emilia, Modena, Italy and Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland; **Charidimos Tzagarakis** FRCPsych, PhD, Organization Against Drugs (OKANA), Athens, Greece; Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States **Jeremy E Solly**, MRCPsych, PhD, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; Department of Psychiatry, University of Cambridge, UK; **Samuel J. Westwood**, PhD; Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; **Valeria Parlatini**, MRCPsych, PhD Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK and Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; **Henrietta Bowden-Jones** FRCPsych, PhD, National Problem Gambling Clinic & National Centre for Gaming Disorders, London, UK; and Department of Psychiatry, University of Cambridge, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK; **Jon E Grant** MD, PhD, Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA; **Samuele Cortese** MD, PhD, Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK; Clinical and Experimental Sciences (CNS

and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK; Solent NHS Trust, Southampton, UK; University of Nottingham, Nottingham, UK; Department of Child and Adolescent Psychiatry, New York University Grossman School of Medicine, New York; **Samuel R Chamberlain**; MRCPsych, PhD Department of Psychiatry, Faculty of Medicine, University of Southampton, UK; and Southern Health NHS Foundation Trust, Southampton, UK

REFERENCES

1. The Lancet Public Health. Gambling: a neglected public health issue. Lancet Public Heal [Internet]. 2021 Jan 1 [cited 2023 May 16];6(1):e1. Available from: http://www.thelancet.com/article/S2468266720302905/fulltext

2. Grant JE, Chamberlain SR. Gambling and substance use: Comorbidity and treatment implications. Prog Neuro-Psychopharmacology Biol Psychiatry. 2020 Apr 20;99:109852.

3. Bowden-Jones H, Hook RW, Grant JE, Ioannidis K, Corazza O, Fineberg NA, et al. Gambling Disorder in the United Kingdom: key research priorities and the urgent need for independent research funding. The lancet Psychiatry [Internet]. 2022 Apr 1 [cited 2023 May 16];9(4):321. Available from: /pmc/articles/PMC7612512/

4. ICD-11. ICD-11 for Mortality and Morbidity Statistics [Internet]. 2021 [cited 2021 Sep 19]. Available from: https://icd.who.int/browse11/l-m/en#/http%3A%2F%2Fid.who.int%2Ficd%2Fentity%2F263852475

5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, D.C: American Psychiatric Association; 2013. Section III.

6. Bowden-Jones H, Drummond C, Thomas S. Rapid evidence review of the evidence-based treratment for Gambling disorder in Britain [Internet]. RCPsych. 2016. p. 1–5. Available from: https://www.rcpsych.ac.uk/docs/default-source/members/faculties/addictions-psychiatry/addictions-resources-for-specialists-rapid-evidence-for-gambling.pdf?sfvrsn=736e144a_2

7.   Thomas SA, Merkouris SS, Radermacher HL, Dowling NA, Misso ML, Anderson CJ, et al. Australian guideline for treatment of problem gambling: an abridged outline. Med J Aust [Internet]. 2011 Dec 12 [cited 2022 Jul 24];195(11):664–5. Available from: https://www.mja.com.au/journal/2011/195/11/australian-guideline-treatment-problem-gambling-abridged-outline

8.   Goslar M, Leibetseder M, Muench HM, Hofmann SG, Laireiter AR. Pharmacological Treatments for Disordered Gambling: A Meta-analysis. J Gambl Stud [Internet]. 2019 Jun 1 [cited 2023 May 30];35(2):415–45. Available from: https://pubmed.ncbi.nlm.nih.gov/30570700/

9.   Dowling N, Merkouris S, Lubman D, Thomas S, Bowden-Jones H, Cowlishaw S. Pharmacological interventions for the treatment of disordered and problem gambling. Cochrane Database Syst Rev [Internet]. 2022 Sep 22 [cited 2023 May 23];2022(9). Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008936.pub2/full

10.   Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Chapter 12 Network Meta-Analysis | Doing Meta-Analysis in R: A hands on guide. In: Doing Meta-Analysis in R: A hands on guide [Internet]. FL and London: Chapman & Hall/CRC Press (Taylor & Francis); 2021 [cited 2023 Jun 7]. Available from: https://bookdown.org/MathiasHarrer/Doing_Meta_Analysis_in_R/netwma.html

11.   Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making [Internet]. 2013 Jul [cited 2023 Jun 7];33(5):607–17. Available from: https://pubmed.ncbi.nlm.nih.gov/23104435/

12.   Schuit E, Ioannidis JPA. Network meta-analyses performed by contracting companies and commissioned by industry. Syst Rev [Internet]. 2016 Nov 25 [cited 2023 Jun 7];5(1). Available from: https://pubmed.ncbi.nlm.nih.gov/27884175/

13.   NICE. Project information | Harmful gambling: identification, assessment and management | Guidance | NICE [Internet]. 2023 [cited 2023 Jul 21]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ng10210

14.   Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med [Internet]. 2015 Jun 2 [cited 2023 Oct 6];162(11):777–84. Available from: https://pubmed.ncbi.nlm.nih.gov/26030634/

15.   Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry [Internet]. 2018 Sep 1 [cited 2023 May 23];5(9):727–38. Available from: http://www.thelancet.com/article/S2215036618302694/fulltext

16.   Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambl Stud [Internet]. 2005 Dec [cited 2023 Jun 25];21(4):431–43. Available from: https://pubmed.ncbi.nlm.nih.gov/16311876/

17.   Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry [Internet]. 2001 Jun 1 [cited 2022 May 31];49(11):914–21. Available from: https://pubmed.ncbi.nlm.nih.gov/11377409/

18.   Busner J, Targum SD. The Clinical Global Impressions Scale: Applying a Research Tool in Clinical Practice. Psychiatry (Edgmont) [Internet]. 2007 Jul [cited 2023 Jun 25];4(7):28. Available from: /pmc/articles/PMC2880930/

19.   Sheehan D V., Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol [Internet]. 1996 [cited 2023 Jun 25];11 Suppl 3(SUPPL. 3):89–95. Available from: https://pubmed.ncbi.nlm.nih.gov/8923116/

20.   Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd Editio. Chichester (UK): John Wiley & Sons; 2019.

21.   Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-

analysis. Ann Intern Med [Internet]. 2013 Jul 16 [cited 2023 Sep 27];159(2):130–7. Available from: https://pubmed.ncbi.nlm.nih.gov/23856683/

22.   Rhodes KM, Turner RM, White IR, Jackson D, Spiegelhalter DJ, Higgins JPT. Implementing informative priors for heterogeneity in meta□analysis using meta□regression and pseudo data. Stat Med [Internet]. 2016 Dec 12 [cited 2023 Jun 25];35(29):5495. Available from: /pmc/articles/PMC5111594/

23.   Veroniki AA, Higgins HSV, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol [Internet]. 2013 Feb [cited 2023 Sep 27];42(1):332–45. Available from: https://pubmed.ncbi.nlm.nih.gov/23508418/

24.   Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol [Internet]. 2011 Feb [cited 2023 Aug 9];64(2):163–71. Available from: https://pubmed.ncbi.nlm.nih.gov/20688472/

25.   Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Giovane C Del, Egger M, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLOS Med [Internet]. 2020 Apr 2 [cited 2023 Jun 25];17(4):e1003082. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003082

26.   Cochrane. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias [Internet]. 2023 [cited 2023 Jun 25]. Available from: https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials

27.   Gamer M, Lemon J, Fellows I, Singh P. Various Coefficients of Interrater Reliability and Agreement - Package "irr" [Internet]. CRAN Project. 2022. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://cran.r-project.org/web/packages/irr/irr.pdf

28.   Hollander E, Pallanti S, Allen A, Sood E, Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry [Internet]. 2005 Jan [cited 2023 Aug 5];162(1):137–45. Available from:

https://pubmed.ncbi.nlm.nih.gov/15625212/

29. Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LRN, Donahue CB, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014;75(1):39–45.

30. Alho H, Mäkelä N, Isotalo J, Toivonen L, Ollikainen J, Castrén S. Intranasal as needed naloxone in the treatment of gambling disorder: A randomised controlled trial. Addict Behav [Internet]. 2022 Feb 1 [cited 2023 Jun 25];125. Available from: https://pubmed.ncbi.nlm.nih.gov/34634640/

31. Clark SD, Abi-Dargham A. The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence. Biol Psychiatry. 2019 Oct 1;86(7):502–11.

32. Victorri-Vigneau C, Spiers A, Caillet P, Bruneau M, IGNACE-consortium, Challet-Bouju G, et al. Opioid Antagonists for Pharmacological Treatment of Gambling Disorder: Are they Relevant? Curr Neuropharmacol [Internet]. 2018 Jul 19 [cited 2023 Oct 13];16(10):1418. Available from: /pmc/articles/PMC6295935/

33. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet [Internet]. 2019 Sep 14 [cited 2023 Oct 13];394(10202):939–51. Available from: http://www.thelancet.com/article/S0140673619311353/fulltext

34. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, et al. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry [Internet]. 2013 Mar [cited 2023 Jun 25];14(2):121–8. Available from: https://pubmed.ncbi.nlm.nih.gov/21486110/

35. de Brito AMC, de Almeida Pinto MG, Bronstein G, Carneiro E, Faertes D, Fukugawa V, et al. Topiramate Combined with Cognitive Restructuring for the Treatment of Gambling Disorder: A Two-Center, Randomized, Double-Blind Clinical Trial. J Gambl Stud [Internet]. 2017 Mar 1 [cited 2023 Jun

25];33(1):249–63. Available from: https://link.springer.com/article/10.1007/s10899-016-9620-z

36.   Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate's effects for individuals with alcohol use disorders. Alcohol Clin Exp Res [Internet]. 2014 [cited 2023 Oct 13];38(6):1481. Available from: /pmc/articles/PMC4047180/

37.   Dannon PN, Rosenberg O, Schoenfeld N, Kotler M. Acamprosate and baclofen were not effective in the treatment of pathological gambling: Preliminary blind rater comparison study. Front Psychiatry. 2011 Jun 6;2(JUN):10985.

38.   Saiz-Ruiz J, Blanco C, Ibáñez A, Masramon X, Gómez MM, Madrigal M, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry [Internet]. 2005 [cited 2023 Aug 5];66(1):28–33. Available from: https://pubmed.ncbi.nlm.nih.gov/15669885/

39.   Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LRN, Donahue CB, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry [Internet]. 2014 [cited 2023 Aug 5];75(1):39–45. Available from: https://pubmed.ncbi.nlm.nih.gov/24345329/

40.   Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry [Internet]. 2007 Sep 15 [cited 2022 Mar 25];62(6):652–7. Available from: https://pubmed.ncbi.nlm.nih.gov/17445781/

41.   Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LRN, Donahue CB, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry [Internet]. 2014 [cited 2022 Mar 25];75(1):39–45. Available from: https://pubmed.ncbi.nlm.nih.gov/24345329/

42.   Lorains FK, Cowlishaw S, Thomas SA. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction [Internet]. 2011 Mar 1 [cited 2023 Aug 5];106(3):490–8. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1360-0443.2010.03300.x

43. Grant JE, Odlaug BL, Suck WK. N-Acetylcysteine, a Glutamate Modulator, in the Treatment of Trichotillomania: A Double-blind, Placebo-Controlled Study. Arch Gen Psychiatry [Internet]. 2009 Jul 1 [cited 2023 Aug 5];66(7):756–63. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/483113

44. Hollander E, Frenkel M, Decaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine. Am J Psychiatry [Internet]. 1992 [cited 2023 Aug 5];149(5):710–1. Available from: https://pubmed.ncbi.nlm.nih.gov/1575267/

45. Kayser RR. Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder. J Clin Psychiatry [Internet]. 2020 Sep 9 [cited 2023 Aug 5];81(5). Available from: /pmc/articles/PMC7495343/

46. Kovanen L, Basnet S, Castrén S, Pankakoski M, Saarikoski ST, Partonen T, et al. A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling. Eur Addict Res [Internet]. 2016 Jan 1 [cited 2023 May 30];22(2):70–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26339899/

47. Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl). 2008 Nov;200(4):521–7.

48. Grant JE, Potenza MN, Hollander E, Cynningham-Williams R, Nurminen T, Smits G, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry [Internet]. 2006 Feb [cited 2022 May 25];163(2):303–12. Available from: https://pubmed.ncbi.nlm.nih.gov/16449486/

49. Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry [Internet]. 2010 Oct [cited 2022 May 25];197(4):330–1. Available from: https://pubmed.ncbi.nlm.nih.gov/20884959/

50. Browne CA, Smith T, Lucki I. Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression. Eur J Pharmacol [Internet]. 2020 Apr 5 [cited 2023 Oct

13];872. Available from: https://pubmed.ncbi.nlm.nih.gov/31991139/

51. Nalmefene. Meyler's Side Eff Drugs [Internet]. 2016 Jan 1 [cited 2023 Oct 13];12–3. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780444537171011276

52. Soyka M. Nalmefene for the treatment of alcohol dependence: a current update. Int J Neuropsychopharmacol [Internet]. 2014 [cited 2023 Oct 4];17(4):675–84. Available from: https://pubmed.ncbi.nlm.nih.gov/24246244/

53. Chamberlain SR, Ioannidis K, Bowden-Jones H. The UK Gambling White Paper: comments on implementation and timing. Compr Psychiatry. 2023;

Online Supplement; Pharmacological management of gambling disorder: A Systematic review and Network Meta-Analysis - Ioannidis et al. (2023)

Contents

§S1 – Methods details

Below we provide additional clarifications on the methods. Such details were not deviations from the original protocol published in PROSPERO, but rather a more comprehensive presentation of the full methodology used here, for reasons of clarity and transparency.

Inclusion/exclusion criteria

The co-existence of an intervention e.g. psychosocial support, cognitive restructuring, motivational interviewing, imaginal desensitization, attendance to Gamblers Anonymous (GA) meetings or equivalent was

not an exclusion criterion, as long as those interventions existed equally in all respective study arms. There was no study in the sample breaching these criteria.

The existence of comorbidities in the sample was not an exclusion criterion, however, if the study specifically included a sample with a primary psychiatric condition in the whole sample (main inclusion criterion), then these studies were to be excluded, as this would violate the transitivity assumption. This applied to two studies in the final set, which were excluded from NMA (1,2).

The need to have outcomes measures at two time points was not an inclusion criterion for NMA, as NMA can be performed without baseline outcome measures. This applies universally to all NMAs but was not explicitly stated in the original protocol publication.

When there were no events in both arms in respect to the tolerability analysis, we opted to exclude those studies from NMA as per Cochrane Handbook 16.9.3 (studies with no events (3).

Data collection

Where total sample size (N) from Intention-To-Treat (ITT) analyses was provided then this was used; if this was not given, then N was taken from the number of completers of the study.

Data were collected from manuscript figures where this was deemed possible and appropriate.

We included multi-arm studies, however, using the approach provided by Cochrane Handbook (5.1 - 7.7 Extracting study results and converting to the desired format) (4) to collapse multi-arm trials in a two arms (active vs placebo) for inclusion in the NMA.

We used the Cochrane Handbook approach (5.1 - 7.7 Extracting study results and converting to the desired format) (4) to reverse calculate standard deviations or standard errors from 95%CIs or p-values where appropriate.

Main analysis

If a study reported results from multiple scales, we analysed the results from one scale by using the following hierarchy: PG-YBOCS; G-SAS, CGI-I.

CGI reported as % of responders was not further considered in analyses, as this format was not accompanied by a measure of variability.

Meta-regression and subgroup analyses

We did not use duration of treatment for meta-regression analyses. Our approach was to collect the last reported observation as end-of-treatment and use that as the final end point. While theoretically differences in treatment duration can violate the transitivity assumption, the vast majority of studies in this sample used similar shorts durations therefore we assumed that the transitivity assumption was met (e.g. 12-16 weeks). We did not use mode of administration (e.g. oral tabs, caps, inhalation/nasal spray, injection etc) of treatment for subgroup analyses because all studies used oral preparations, apart from one (5) which used Naloxone Nasal spray.

§S2 – PRISMA-NMA checklist

PRISMA NMA (6) Checklist of Items to Include When Reporting A Systematic Review Involving a Network Meta-analysis

Section/Topic	Item #	Checklist Item	Reported on Page #
TITLE			
Title	1	Identify the report as a systematic review *incorporating a network meta-analysis (or related form of meta-analysis).*	p.1
ABSTRACT			
Structured summary	2	Provide a structured summary	p.3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known, *including mention of why a network meta-analysis has been conducted.*	p.4-5
Objectives	4	Provide an explicit statement of questions being addressed, with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	p.5
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists and if and where it can be accessed (e.g., Web address); and, if available, provide registration information, including registration number.	p.5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. *Clearly describe eligible treatments included in the treatment network, and note whether any have been clustered or merged into the same node (with justification).*	p.5 and Supplement §S5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	p.6-7 and Supplement

			§S3
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supplement §S3
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	p.6 and Supplement §S1
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	p.6-7 and Supplement §S1
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	p.7 and Supplement §S1
Geometry of the network	**S1**	Describe methods used to explore the geometry of the treatment network under study and potential biases related to it. This should include how the evidence base has been graphically summarized for presentation, and what characteristics were compiled and used to describe the evidence base to readers.	p.11 Figure 2 and Supplement §S5
Risk of bias within individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	p.8 Supplement §S5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means). *Also describe the use of additional summary measures assessed, such as treatment rankings and surface under the cumulative ranking curve (SUCRA) values, as well as modified approaches used to present summary findings from meta-analyses.*	p.7-8 Supplement §S9
Planned methods of analysis	14	Describe the methods of handling data and combining results of studies for each network meta-analysis. This should include, but not be limited to: *Handling of multi-arm trials;*	p.7 Supplement §S1

		Selection of variance structure;	
		Selection of prior distributions in Bayesian analyses; and	
		Assessment of model fit.	
Assessment of Inconsistency	S2	Describe the statistical methods used to evaluate the agreement of direct and indirect evidence in the treatment network(s) studied. Describe efforts taken to address its presence when found.	p.8 Supplement §S7
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	p.8 Supplement §S5
Additional analyses	16	Describe methods of additional analyses if done, indicating which were pre-specified. This may include, but not be limited to, the following: Sensitivity or subgroup analyses; Meta-regression analyses; *Alternative formulations of the treatment network; and* *Use of alternative prior distributions for Bayesian analyses (if applicable).*	p.7 Supplement §S8

RESULTS†

Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Figure 1
Presentation of network structure	S3	Provide a network graph of the included studies to enable visualization of the geometry of the treatment network.	Figure 2
Summary of network geometry	S4	Provide a brief overview of characteristics of the treatment network. This may include commentary on the abundance of trials and randomized patients for the different interventions and pairwise comparisons in the network, gaps of evidence in the treatment network, and potential biases reflected by the network structure.	Supplement §S5

Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Supplement §S5
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment.	Supplement §S5
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: 1) simple summary data for each intervention group, and 2) effect estimates and confidence intervals. *Modified approaches may be needed to deal with information from larger networks.*	Figure 3
Synthesis of results	21	Present results of each meta-analysis done, including confidence/credible intervals. *In larger networks, authors may focus on comparisons versus a particular comparator (e.g. placebo or standard care), with full findings presented in an appendix. League tables and forest plots may be considered to summarize pairwise comparisons.* If additional summary measures were explored (such as treatment rankings), these should also be presented.	Figure 3
Exploration for inconsistency	**S5**	Describe results from investigations of inconsistency. This may include such information as measures of model fit to compare consistency and inconsistency models, *P* values from statistical tests, or summary of inconsistency estimates from different parts of the treatment network.	p.8 Supplement §S7
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies for the evidence base being studied.	p.8 Supplement §S5
Results of additional analyses	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression analyses, *alternative network geometries studied, alternative choice of prior distributions for Bayesian analyses,* and so forth).	p.8 Supplement §S8

DISCUSSION

Summary of evidence	24	Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy-makers).	p.20
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified	p.19-20

research, reporting bias). *Comment on the validity of the assumptions, such as transitivity and consistency.*

Comment on any concerns regarding network geometry (e.g., avoidance of certain comparisons).

Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	p.20

FUNDING

Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. This should also include information regarding whether funding has been received from manufacturers of treatments in the network and/or whether some of the authors are content experts with professional conflicts of interest that could affect use of treatments in the network.	p.21

§S3 – Search strategy including online databases and clinical registers

Sources were searched included the following:

MEDLINE, EMBASE, PsycINFO, PubMed, CINAHL, AMED, and the Cochrane Database of Systematic Reviews, ERIC and Web of Science (including Science Citation Index Expanded (SCI-EXPANDED), Social Science Citation Index (SSCI), Conference Proceedings Citation Index-Science (CPCI-S) and Conference Proceedings Citation Index-Social Science and Humanities (CPCI-SSH)) via Web of Knowledge.

PubMed

(("Gambling"[Mesh] OR "Gambling"[tw] OR "Gambling Disorder"[tw] OR "Gambling Disorders"[tw] OR "Pathological Gambling"[tw] OR "Gambling Addiction"[tw] OR "Disordered Gambling"[tw] OR "Pathological Gambler"[tw] OR "Disordered Gambler"[tw] OR "Pathological Gamblers"[tw] OR "Disordered Gamblers"[tw] OR "ludomania"[tw]) AND ("Gambling/drug therapy"[Mesh] OR "Drug Therapy"[mesh] OR "Drug therapy"[tiab] OR "Drug therap*"[tiab] OR "Pharmacological Treatments"[tw] OR "Pharmacological Treatment"[tw] OR "Pharmacologic Treatments"[tw] OR "Pharmacologic Treatment"[tw] OR "Pharmacological Therapy"[tw] OR "Pharmacologic Therapy"[tw] OR "Pharmacotherapy"[tw] OR

"Pharmacotherap*"[tw] OR "Psychopharmacotherapy"[tw] OR "Psychopharmacotherap*"[tw] OR "Drug treatment"[tw] OR "Drug treat*"[tw] OR "Medication"[tw] OR "Medications"[tw] OR "Medicat*"[tw] OR "Pharmaceutical Preparations"[Mesh] OR "pharmaco*"[tw] OR "Narcotic Antagonists"[Pharmacological Action] OR "Narcotic Antagonists"[mesh] OR "Dopamine Agents"[Mesh] OR "Dopamine Agents"[Pharmacological Action] OR "Hypnotics and Sedatives"[Pharmacological Action] OR "Hypnotics and Sedatives"[mesh] OR "Antidepressive Agents"[Pharmacological Action] OR "Antidepressive Agents"[mesh] OR "Antipsychotic Agents"[Mesh] OR "Antipsychotic Agents"[Pharmacological Action] OR "Catechol O- Methyltransferase Inhibitors"[mesh] OR "Catechol O-Methyltransferase Inhibitors"[PharmacologicalAction] OR "Psychotropic Drugs"[Mesh] OR "Psychotropic Drugs"[Pharmacological Action] OR "Alcohol Deterrents"[Mesh] OR "Alcohol Deterrents"[pharmacological action] OR "Anticonvulsants"[Pharmacological Action] OR "Anticonvulsants"[mesh] OR "Antiparkinson Agents"[Mesh] OR "Antiparkinson Agents"[Pharmacological Action] OR "Naloxone"[Mesh] OR "Naltrexone"[Mesh] OR "Topiramate"[Mesh] OR "Acetylcysteine"[Mesh] OR "Tolcapone"[Mesh] OR "nalmefene"[Supplementary Concept] OR "Narcotic Antagonists"[mesh] OR "Narcotic Antagonists"[Pharmacological Action] OR "Amantadine"[Mesh] OR "Memantine"[Mesh] OR "Modafinil"[Mesh] OR "Olanzapine"[Mesh] OR "Bupropion"[Mesh] OR "Escitalopram"[Mesh] OR "Serotonin Uptake Inhibitors"[Pharmacological Action] OR "Serotonin Uptake Inhibitors"[mesh] OR "Paroxetine"[Mesh] OR "Fluvoxamine"[Mesh] OR "Sertraline"[Mesh] OR "Lithium Carbonate"[Mesh] OR "Valproic Acid"[Mesh] OR "Clomipramine"[Mesh] OR "Antidepressive Agents, Tricyclic"[Pharmacological Action] OR "Antidepressive Agents, Tricyclic"[mesh] OR naloxone[tw] OR naltrexone[tw] OR topiramate[tw] OR n-acetylcysteine[tw] OR tolcapone[tw] OR nalmefene[tw] OR amantadine[tw] OR memantine[tw] OR modafinil[tw] OR olanzapine[tw] OR bupropion[tw] OR escitalopram[tw] OR

paroxetine[tw] OR fluvoxamine[tw] OR sertraline[tw] OR lithium[tw] OR valproate[tw] OR clomipramine[tw] OR "Placebos"[Mesh] OR "Placebo Effect"[Mesh] OR "Placebos"[tw] OR "Placebo"[tw]) AND ((randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab] NOT (animals [mh] NOT humans [mh])) OR ("Cross-Over Studies"[Mesh] OR "Crossover"[tw] OR "Cross over"[tw])))

MEDLINE (OVID)

(("Gambling"/ OR "Gambling".mp OR "Gambling Disorder".mp OR "Gambling Disorders".mp OR"Pathological Gambling".mp OR "Gambling Addiction".mp OR "Disordered Gambling".mp OR"Pathological Gambler".mp OR "Disordered Gambler".mp OR "Pathological Gamblers".mp OR "Disordered Gamblers".mp OR "ludomania".mp) AND ("Gambling"/dt OR exp "Drug Therapy"/ OR "Drug therapy".ti,ab OR "Drug therap*".ti,ab OR "Pharmacological Treatments".mp OR "Pharmacological Treatment".mp OR "Pharmacologic Treatments".mp OR "Pharmacologic Treatment".mp OR "Pharmacological Therapy".mp OR "Pharmacologic Therapy".mp OR "Pharmacotherapy".mp OR "Pharmacotherap*".mp OR "Psychopharmacotherapy".mp OR "Psychopharmacotherap*".mp OR "Drug treatment".mp OR "Drug treat*".mp OR "Medication".mp OR "Medications".mp OR "Medicat*".mp OR exp "Pharmaceutical Preparations"/ OR "pharmaco*".mp OR exp "Naloxone"/ OR exp "Naltrexone"/ OR exp "Topiramate"/ OR exp "Acetylcysteine"/ OR exp "Tolcapone"/ OR exp "nalmefene"/ OR exp "Narcotic Antagonists"/ OR exp "Amantadine"/ OR exp "Memantine"/ OR exp "Modafinil"/ OR exp "Olanzapine"/ OR exp "Bupropion"/ OR exp "Escitalopram"/ OR exp "Serotonin Uptake Inhibitors"/ OR exp "Paroxetine"/ OR exp "Fluvoxamine"/ OR exp "Sertraline"/ OR exp "Lithium Carbonate"/ OR

exp "Valproic Acid"/ OR exp "Clomipramine"/ OR exp "Antidepressive Agents, Tricyclic"/ OR naloxone.mp OR naltrexone.mp OR topiramate.mp OR n-acetylcysteine.mp OR tolcapone.mp OR nalmefene.mp OR amantadine.mp OR memantine.mp OR modafinil.mp OR olanzapine.mp OR bupropion.mp OR escitalopram.mp OR paroxetine.mp OR fluvoxamine.mp OR sertraline.mp OR lithium.mp OR valproate.mp OR clomipramine.mp OR exp "Narcotic Antagonists"/ OR exp "Dopamine Agents"/ OR exp "Hypnotics and Sedatives"/ OR exp "Antidepressive Agents"/ OR exp "Antipsychotic Agents"/ OR exp "Catechol O-Methyltransferase Inhibitors"/ OR exp "Psychotropic Drugs"/ OR exp "Alcohol Deterrents"/ OR exp "Anticonvulsants"/ OR exp "Antiparkinson Agents"/ OR exp "Placebos"/ OR exp "Placebo Effect"/ OR "Placebos".mp OR "Placebo".mp) AND ((exp randomized controlled trial/ OR exp controlled clinical trial/ OR randomized.ti,ab OR placebo.ti,ab OR exp drug therapy/ OR randomly.ti,ab OR trial.ti,ab OR groups.ti,ab NOT (exp animals/ NOT exp humans/)) OR (exp "Cross- Over Studies"/ OR "Crossover".mp OR "Cross over".mp)))

Embase (OVID)

(("Pathological Gambling"/ OR "Gambling".mp OR "Gambling Disorder".mp OR "Gambling Disorders".mp OR "Pathological Gambling".mp OR "Gambling Addiction".mp OR "Disordered Gambling".mp OR "Pathological Gambler".mp OR "Disordered Gambler".mp OR "Pathological Gamblers".mp OR "Disordered Gamblers".mp OR "ludomania".mp) AND ("Pathological Gambling"/dt OR exp "Drug Therapy"/ OR "Drug therapy".ti,ab OR "Drug therap*".ti,ab OR "Pharmacological Treatments".mp OR "Pharmacological Treatment".mp OR "Pharmacologic Treatments".mp OR "Pharmacologic Treatment".mp OR "Pharmacological Therapy".mp OR "Pharmacologic Therapy".mp OR "Pharmacotherapy".mp OR "Pharmacotherap*".mp OR "Psychopharmacotherapy".mp OR "Psychopharmacotherap*".mp OR "Drug treatment".mp OR "Drug

treat*".mp OR "Medication".mp OR "Medications".mp OR "Medicat*".mp OR exp "Drug"/ OR "pharmaco*".mp OR exp "Naloxone"/ OR exp "Naltrexone"/ OR exp "Topiramate"/ OR exp "Acetylcysteine"/ OR exp "Tolcapone"/ OR exp "nalmefene"/ OR exp "Narcotic Antagonist"/ OR exp "Amantadine"/ OR exp "Memantine"/ OR exp "Modafinil"/ OR exp "Olanzapine"/ OR exp "Bupropion"/ OR exp "Escitalopram"/ OR exp "Serotonin Uptake Inhibitor"/ OR exp "Paroxetine"/ OR exp "Fluvoxamine"/ OR exp "Sertraline"/ OR exp "Lithium Carbonate"/ OR exp "Valproic Acid"/ OR exp "Clomipramine"/ OR exp "Tricyclic Antidepressant Agent"/ OR naloxone.mp OR naltrexone.mp OR topiramate.mp OR n- acetylcysteine.mp OR tolcapone.mp OR nalmefene.mp OR amantadine.mp OR memantine.mp OR modafinil.mp OR olanzapine.mp OR bupropion.mp OR escitalopram.mp OR paroxetine.mp OR fluvoxamine.mp OR sertraline.mp OR lithium.mp OR valproate.mp OR clomipramine.mp OR exp "Narcotic Antagonist"/ OR exp "dopamine receptor stimulating agent"/ OR exp "Hypnotic Sedative Agent"/ OR exp "Antidepressant Agent"/ OR exp "Neuroleptic Agent"/ OR exp "Catechol OMethyltransferase Inhibitor"/ OR exp "Psychotropic Agent"/ OR exp "drugs used in the treatment of addiction"/ OR exp "Anticonvulsive Agent"/ OR exp "Antiparkinson Agent"/ OR exp "Placebo"/ OR exp "Placebo Effect"/ OR "Placebos".mp OR "Placebo".mp) AND ((Randomized controlled trial/ OR Controlled clinical study/ OR random$.ti,ab. OR randomization/ OR intermethod comparison/ OR placebo.ti,ab. OR (compare OR compared OR comparison).ti. OR ((evaluated OR evaluate OR evaluating OR assessed OR assess) and (compare OR compared OR comparing OR comparison)).ab. OR (open adj label).ti,ab. OR ((double OR single OR doubly OR singly) adj (blind OR blinded OR blindly)).ti,ab. OR double blind procedure/ OR parallel group$1.ti,ab. OR (crossover OR cross over).ti,ab. OR ((assign$ OR match OR matched OR allocation) adj5 (alternate OR group$1 OR intervention$1 OR patient$1 OR subject$1 OR participant$1)).ti,ab. OR (assigned OR allocated).ti,ab. OR (controlled adj7 (study OR design OR trial)).ti,ab. OR (volunteer OR volunteers).ti,ab. OR human experiment/ OR trial.ti.) not (((random$ adj sampl$ adj7

("cross section $" OR questionnaire$1 OR survey$ OR database$1)).ti,ab. not (comparative study/ OR controlled study/ OR randomi?ed controlled.ti,ab. OR randomly assigned.ti,ab.)) OR (Cross-sectional study/ not (randomized controlled trial/ OR controlled clinical study/ OR controlled study/ OR randomi?ed controlled.ti,ab. OR control group$1.ti,ab.)) OR (((case adj control$) and random$) not randomi?ed controlled).ti,ab. OR (Systematic review not (trial OR study)).ti. OR (nonrandom$ not random$).ti,ab. OR "Random field$".ti,ab. OR (random cluster adj3 sampl$).ti,ab. OR ((review.ab. and review.pt.) not trial.ti.) OR ("we searched".ab. and (review.ti. OR review.pt.)) OR "update review".ab. OR (databases adj4 searched).ab. OR ((rat OR rats OR mouse OR mice OR swine OR porcine OR murine OR sheep OR lambs OR pigs OR piglets OR rabbit OR rabbits OR cat OR cats OR dog OR dogs OR cattle OR bovine OR monkey OR monkeys OR trout OR marmoset$1).ti. and animal experiment/) OR (Animal experiment/ not (human experiment/ OR human/))) OR (exp "Crossover Procedure"/ OR "Crossover".mp OR "Cross over".mp)))

PsyclNFO (EbscoHOST)

((TI("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania") OR MA("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers") OR SU("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania") OR AB("Pathological Gambling" OR "Gambling" OR

"Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania")) AND (TI("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment&quo; OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo") OR MA("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological

Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo") OR SU("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR

"Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo") OR AB("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR

"Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo")) AND (TI(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over") OR MA(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over") OR SU(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over") OR AB(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over")))

Emcare (OVID)

(("Pathological Gambling"/ OR "Gambling".mp OR "Gambling Disorder".mp OR "Gambling Disorders".mp OR "Pathological Gambling".mp OR "Gambling Addiction".mp OR "Disordered Gambling".mp OR "Pathological Gambler".mp OR "Disordered Gambler".mp OR "Pathological

Gamblers".mp OR "Disordered Gamblers".mp OR "ludomania".mp) AND (exp "Drug Therapy"/ OR "Drug therapy".ti,ab OR "Drug therap*".ti,ab OR "Pharmacological Treatments".mp OR "Pharmacological Treatment".mp OR "Pharmacologic Treatments".mp OR "Pharmacologic Treatment".mp OR "Pharmacological Therapy".mp OR "Pharmacologic Therapy".mp OR "Pharmacotherapy".mp OR "Pharmacotherap*".mp OR "Psychopharmacotherapy".mp OR "Psychopharmacotherap*".mp OR "Drug treatment".mp OR "Drug treat*".mp OR "Medication".mp OR "Medications".mp OR "Medicat*".mp OR exp "Drug"/ OR "pharmaco*".mp OR exp "Narcotic Antagonist"/ OR exp "dopamine receptor stimulating agent"/ OR exp "Hypnotic Sedative Agent"/ OR exp "Antidepressant Agent"/ OR exp "Neuroleptic Agent"/ OR exp "Catechol OMethyltransferase Inhibitor"/ OR exp "Psychotropic Agent"/ OR exp "drugs used in the treatment of addiction"/ OR exp "Anticonvulsive Agent"/ OR exp "Antiparkinson Agent"/ OR exp "Naloxone"/ OR exp "Naltrexone"/ OR exp "Topiramate"/ OR exp "Acetylcysteine"/ OR exp "Tolcapone"/ OR exp "nalmefene"/ OR exp "Narcotic Antagonist"/ OR exp "Amantadine"/ OR exp "Memantine"/ OR exp "Modafinil"/ OR exp "Olanzapine"/ OR exp "Bupropion"/ OR exp "Escitalopram"/ OR exp "Serotonin Uptake Inhibitor"/ OR exp "Paroxetine"/ OR exp "Fluvoxamine"/ OR exp "Sertraline"/ OR exp "Lithium Carbonate"/ OR,exp "Valproic Acid"/ OR exp "Clomipramine"/ OR exp "Tricyclic Antidepressant Agent"/ OR naloxone.mp OR naltrexone.mp OR topiramate.mp OR n-acetylcysteine.mp OR tolcapone.mp OR nalmefene.mp OR amantadine.mp OR memantine.mp OR modafinil.mp OR olanzapine.mp OR bupropion.mp OR escitalopram.mp OR paroxetine.mp OR fluvoxamine.mp OR sertraline.mp OR lithium.mp OR valproate.mp OR clomipramine.mp OR exp "Placebo"/ OR exp "Placebo Effect"/ OR "Placebos".mp OR "Placebo".mp) AND ((Randomized controlled trial/ OR Controlled clinical study/ OR random$.ti,ab. OR randomization/ OR intermethod comparison/ OR placebo.ti,ab. OR (compare OR

compared OR comparison).ti. OR ((evaluated OR evaluate OR evaluating OR assessed OR assess) and (compare OR compared OR comparing OR comparison)).ab. OR (open adj label).ti,ab. OR ((double OR single OR doubly OR singly) adj (blind OR blinded OR blindly)).ti,ab. OR double blind procedure/ OR parallel group$1.ti,ab. OR (crossover OR cross over).ti,ab. OR ((assign$ OR match OR matched OR allocation) adj5 (alternate OR group$1 OR intervention$1 OR patient$1 OR subject$1 OR participant$1)).ti,ab. OR (assigned OR allocated).ti,ab. OR (controlled adj7 (study OR design OR trial)).ti,ab. OR (volunteer OR volunteers).ti,ab. OR human experiment/ OR trial.ti.) not (((random$ adj sampl$ adj7 ("cross section$" OR questionnaire$1 OR survey$ OR database$1)).ti,ab. Not (comparative study/ OR controlled study/ OR randomi?ed controlled.ti,ab. OR randomly assigned.ti,ab.)) OR (Cross-sectional study/ not (randomized controlled trial/ OR controlled clinical study/ OR controlled study/ OR randomi?ed controlled.ti,ab. OR control group$1.ti,ab.)) OR (((case adj control$) and random$) not randomi?ed controlled).ti,ab. OR (Systematic review not (trial OR study)).ti. OR (nonrandom$ not random$).ti,ab. OR "Random field$".ti,ab. OR (random cluster adj3 sampl$).ti,ab. OR ((review.ab. and review.pt.) not trial.ti.) OR ("we searched".ab. and (review.ti. OR review.pt.)) OR "update review".ab. OR (databases adj4 searched).ab. OR ((rat OR rats OR mouse OR mice OR swine OR porcine OR murine OR sheep OR lambs OR pigs OR piglets OR rabbit OR rabbits OR cat OR cats OR dog OR dogs OR cattle OR bovine OR monkey OR monkeys OR trout OR marmoset$1).ti. and animal experiment/) OR (Animal experiment/ not (human experiment/ OR human/))) OR (exp "Crossover Procedure"/ OR "Crossover".mp OR "Cross over".mp)))

Cochrane Library

(("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania") AND ("Drug Therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR

"Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "Pharmaceutical Preparations" OR "pharmaco*" OR "Narcotic Antagonists" OR "Narcotic Antagonists" OR "Dopamine Agents" OR "Dopamine Agents" OR "Hypnotics and Sedatives" OR "Hypnotics and Sedatives" OR "Antidepressive Agents" OR "Antidepressive Agents" OR "Antipsychotic Agents" OR "Antipsychotic Agents" OR "Catechol O-Methyltransferase Inhibitors" OR "Catechol O-Methyltransferase Inhibitors" OR "Psychotropic Drugs" OR "Psychotropic Drugs" OR "Alcohol Deterrents" OR "Alcohol Deterrents" OR "Anticonvulsants" OR "Anticonvulsants" OR "Antiparkinson Agents" OR "Antiparkinson Agents" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Placebos" OR "Placebo Effect" OR "Placebos" OR "Placebo"))

ERIC (EbscoHOST)

((TI("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling

PHARMACOLOGICAL MANAGEMENT OF GAMBLING DISORDER: A NETWORK META-ANALYSIS

Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania") OR SU("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR"Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania") OR AB("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania")) AND (TI("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin

Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo") OR SU("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Naloxone" OR"Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR

lithium OR valproate OR clomipramine OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo") OR AB("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo")) AND (TI(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over") OR MA(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug

therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over") OR AB(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over")))

Web of Science

((TI=("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR"Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania") OR AK=("Pathological Gambling" OR "Gambling" OR "Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction" OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "Pathological Gamblers" OR "Disordered Gamblers" OR "ludomania") OR AB=("Pathological Gambling" OR "Gambling" OR"Gambling Disorder" OR "Gambling Disorders" OR "Pathological Gambling" OR "Gambling Addiction"OR "Disordered Gambling" OR "Pathological Gambler" OR "Disordered Gambler" OR "PathologicalGamblers" OR "Disordered Gamblers" OR "ludomania")) AND (TI=("Drug Therapy" OR "Drug therapy"OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR"Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR"Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR"Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR"Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR "dopamine receptor stimulating

agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent"OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR"drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR"Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo" OR "Naloxone" OR "Naltrexone" OR"Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR"Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram"OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "LithiumCarbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine ORmemantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine ORfluvoxamine OR sertraline OR lithium OR valproate OR clomipramine) OR AK=("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR quot;dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR

"Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR "Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo") OR AB=("Drug Therapy" OR "Drug therapy" OR "Drug therap*" OR "Pharmacological Treatments" OR "Pharmacological Treatment" OR "Pharmacologic Treatments" OR "Pharmacologic Treatment" OR "Pharmacological Therapy" OR "Pharmacologic Therapy" OR "Pharmacotherapy" OR "Pharmacotherap*" OR "Psychopharmacotherapy" OR "Psychopharmacotherap*" OR "Drug treatment" OR "Drug treat*" OR "Medication" OR "Medications" OR "Medicat*" OR "pharmaco*" OR "Narcotic Antagonist" OR "dopamine receptor stimulating agent" OR "Hypnotic Sedative Agent" OR "Antidepressant Agent" OR "Neuroleptic Agent" OR "Catechol OMethyltransferase Inhibitor" OR "Psychotropic Agent" OR "drugs used in the treatment of addiction" OR "Anticonvulsive Agent" OR "Antiparkinson Agent" OR "Naloxone" OR "Naltrexone" OR "Topiramate" OR "Acetylcysteine" OR "Tolcapone" OR "nalmefene" OR "Narcotic Antagonist" OR "Amantadine" OR "Memantine" OR "Modafinil" OR "Olanzapine" OR "Bupropion" OR "Escitalopram" OR "Serotonin Uptake Inhibitor" OR "Paroxetine" OR "Fluvoxamine" OR "Sertraline" OR "Lithium Carbonate" OR "Valproic Acid" OR

"Clomipramine" OR "Tricyclic Antidepressant Agent" OR naloxone OR naltrexone OR topiramate OR n-acetylcysteine OR tolcapone OR nalmefene OR amantadine OR memantine OR modafinil OR olanzapine OR bupropion OR escitalopram OR paroxetine OR fluvoxamine OR sertraline OR lithium OR valproate OR clomipramine OR "Placebo" OR "Placebo Effect" OR "Placebos" OR "Placebo")) AND (TI=(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over") OR AK=(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over") OR AB=(randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR "drug therapy" OR randomly OR trial OR groups OR "Cross-Over Studies" OR "Crossover" OR "Cross over")))

WHO International Clinical Trials Registry Platform (ICTRP), including:

Australian New Zealand Clinical Trials Registry (ANZCTR) (including clinical trials from Therapeutic Goods Administration (TGA)); Brazilian Clinical Trials Registry (ReBec); Chinese Clinical Trial Register (ChiCTR); Clinical Research Information Service (CRiS), Republic of Korea ClinicalTrials.gov (including clinical trials from FDA); Clinical Trials Registry—India (CTRI); Cuban Public Registry of Clinical Trials (RPCEC); EU Clinical Trials Register (EU-CTR) (including clinical trials from the European Medicines Agency (EMA)); German Clinical Trials Register (DRKS); Iranian Registry of Clinical Trials (IRCT); ISRCTN.org (including clinical trials from controlled-trials.com, The Wellcome Trust (UK), UK trials (UK), Action Medical Research (UK), the Medicines and Healthcare products Regulatory Agency (MHRA) and National Research Register); Japan Primary Registries Network (JPRN) (including clinical trials from UMIN-CTR, JapicCTI and JMACCT); Pan African Clinical Trial Registry (PACTR); Sri Lanka Clinical Trials Registry (SLCTR); The Netherlands National Trial Register (NTR); Thai Clinical Trials Register (TCTR); The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA); UK Clinical Trials Gateway; BIOSIS Previews via Web of Knowledge; SEAGLE (OpenGrey); ProQuest Theses and Dissertations; ClinicalTrials.gov; http://www.fda.gov/ ; http://www.ema.europa.eu

All of the above will be searched for any type of Randomized Controlled Trial. Only English language records or available English language translations thereof will be sought. Searches will span a period from the present up to and including the beginning of each database or 1987, whichever comes first.

§S4 - Confidence in Network Meta-Analysis (CINeMA)

Within study bias

Within-study bias refers to shortcomings in the design or conduct of a study that can lead to an estimated relative treatment effect that systematically differs from the truth (7). In our application of CINeMA we considered the per-study contribution matrix in conjunction with RoB 2 assessments to evaluate each relative treatment effect with respect to within-study bias. In CINeMA, a "Risk of bias contributions" section provides a bar chart with each bar corresponding to an estimate of relative effect - each study is represented by a colored area and is proportional to its contribution. We chose "Majority RoB 2" (a level of concern according to the RoB 2 with the greatest total percentage contribution) for all CINeMA assessments.

Reporting bias

Reporting bias occurs when the results included in the systematic review are not a representative sample of the results generated by studies undertaken (7). We used the Risk Of Bias due to Missing Evidence in Network meta-analysis (ROB-MEN) for all assessments (8); within the ROB-MEN approach, we utilized the Outcome Reporting Bias In Trials (ORBIT) to inform our reporting bias ratings (9). Within ROB-MEN, we did not have enough studies (>10) per comparator to conduct graphical or statistical assessment of across study bias. To evaluate small-study effects, we run a network meta-regression model with a measure of precision (e.g. variance or standard error) as the covariate via ROB-MEN (8). This model generates an adjusted relative effect by extrapolating the regression line to the smallest observed variance (the 'largest' study) independently for each comparison. To assess the presence of small-study effects, we compared the obtained adjusted estimates with the original (unadjusted) estimates by looking at the overlap of their corresponding confidence intervals. We regarded a lack of overlap between the two intervals (or between one estimate and the interval for the other estimate) as an indication of small-study effect. ROB-MEN scores were then loaded into CINeMA.

Indirectness

Indirectness refers to the relevance of the included studies to the research question. After assessing the relevance of the included studies in our NMA, we set all indirectness contributions to no concern. In CINeMA, indirectness contributions (matrix) were resolved by majority voting.

Imprecision

CINeMA compares the treatment effects included in the 95% confidence interval with the range of equivalence (7). This helps to understand if the treatment effect extends beyond the area of equivalence and assign the respective confidence ratings. To evaluate imprecision the relative treatment effect that represents a clinically important difference needs to be defined. We defined a clinically important size of effect for continuous outcomes (gambling severity and quality of life) as (-0.20, 0.20) and for dichotomous outcomes (tolerability) as (0.75, 1.25).

Heterogeneity

Variability in the results of studies influences our confidence in the point estimate of a relative treatment effect. If this variability reflects genuine differences between studies, rather than random variation, it is called heterogeneity (7). The CINeMA approach to heterogeneity involves comparisons of results with the pre-specified range of clinical equivalence, therefore, the definition of clinically important difference (see above, imprecision) was used here as well. This evaluates the prediction intervals (which capture heterogeneity) in addition to confidence intervals in relation to the range of equivalence. Confidence ratings for heterogeneity followed the rules outlined in Nikolakopoulou et al. (7).

Incoherence

In network meta-analysis, there may be variation between direct and indirect sources of evidence. This is called incoherence (7). Incoherence testing requires a definition of clinically important difference, and here again we used the definition above (see imprecision). In quality of life NMA, incoherence testing was not statistically possible due to absence of closed loops. In this case, all ratings were set to "some concern".

Overall Confidence rating

We set the overall confidence ratings according to the ruleset below:

We added the 6 domains to achieve a total (overall) confidence score. Each domain contributed by simple addition according to this rule:

Low risk/No concerns = 0; Some concerns = 1; Major Concerns = 3

Overall score: 0-2 = <mark>High</mark>; 3-4 = <mark>Moderate</mark>; 5-6 = <mark>Low</mark>; 7+ = <mark>Very Low</mark>

We used the semi-automated methods of the contribution matrix to pool results in our sample from https://cinema.ispm.unibe.ch/ (10).

§S5 – Characteristics of studies included in the review

#	First Author / Year / Journal	Study Type and Design	Arms	N randomized	Age (mean) /arm	%Male /arm	Route/ dosing scheme	Min. dose†	Max. dose†	Duration	Sponsorship	In NMA?
1	Alho et al.(5) 2022 Add Behav	Double Blind RCT Parallel design, 2 arms	Naloxone vs. Placebo	62/64	43.8 / 45.2	72% / 67%	Intranasal QDS/PRN	4mg	16mg	12-weeks	No	YES
2	De Brito et al.(11) 2017 J Gambl Studies	Double Blind RCT Parallel design, 2 arms	Topiramate vs. Placebo	18/20	50.6 / 45.8	53% / 53%	Oral BD	25mg	300mg	12-weeks	Yes	YES
3	Kovanen et al.(12) 2016 Eur Addict Res	Double Blind RCT Parallel design, 2 arms	Naltrexone vs. Placebo	50/51	47.4 / 44.5	66% / 68%	Oral OD/PRN	50mg	50mg	20-weeks	Yes	YES
4	McElroy et al.(13) 2008 J Clin Psychiatry	Double Blind RCT Parallel design, 2 arms	Olanzapine vs. Placebo	21/21	51.5 / 46.8	38% / 48%	Oral, flexible	2.5mg	15mg	12-weeks	Yes	YES
5	Berlin et al.(14) 2013 WJBP	Double Blind RCT Parallel design, 2 arms	Topiramate vs. Placebo	20/22	50.5 / 44.9	50% / 45%	Oral, flexible	25mg	300mg	14-weeks	Yes	YES
6	Grant et al. (15) 2010 BJPsych	Double Blind RCT Parallel design, 3	Nalmefene vs. Placebo	159/74	N/A	N/A	Oral, titration	5mg	40mg	16-weeks	No	YES

			arms									
7	Grant et al.(16) 2008 J Clin Psychiatry	Double Blind RCT Parallel design, 2 arms	Naltrexone vs. Placebo	58/19	47.8 / 44.7	36% / 47%	Oral, titration	25mg	150mg	17-weeks	No	YES
8	Fong et al.(17) 2008 Pharm Bio Beh	Double Blind RCT Parallel design, 2 arms	Olanzapine vs. Placebo	11/12	46.6 43.6	55% / 50%	Oral, titration	2.5mg	10mg	6-weeks	Yes	YES
9	Black et al. (18) 2007 J Clin Pharmacol	Double Blind RCT Parallel design, 2 arms	Bupropion vs. Placebo	18/21	42.8 43.5	61% / 81%	Oral, flexible	150mg	375mg	12-weeks	No	YES
10	Grant et al.(19) 2006 Am J Psychiatry	Double Blind RCT Parallel design, 4 arms	Nalmefene vs. Placebo	156/51	47.0 / 45.3 / 44.9 / 45.4 / 46.3	54% / 56% / 50% / 67%	Oral, OD	25mg	100mg	16-weeks	Yes	YES
11	Dannon et al. (20) 2005 J Clin Psychopharm	Single-blinded (rater) RCT Parallel design, 2 arms	Naltrexone vs. Bupropion	17/19	34.9 / 36.8	100% / 100%	Oral, flexible	150mg (B), 25mg (N)	450mg (B), 150mg (N)	12-weeks	No	YES
12	Kim et al.(21) 2002 J Clin Psychiatry	Double Blind RCT Parallel design, 2 arms	Paroxetine vs. Placebo	23/22	49.3 / 49.3	43% / 28%	Oral, flexible	20mg	60mg	8-weeks	Yes	YES
13	Grant et al.	Double	Paroxetine	36/40	47.0 /	44% /	Oral,	10mg	60mg	16-	Yes	YES

	(22) 2003 Int Clin Psychopharm acol	Blind RCT Parallel design, 2 arms	vs. Placebo		42.0	75%	flexible			weeks		
14	Kim et al.(23) 2001 Biol Psychiatry	Double Blind RCT Parallel design, 2 arms	Naltrexon e vs. Placebo	20/25	48.0 / 49.0	30% / 40%	Oral, flexible	25mg	250m g	11-weeks	No	YES
15	Hollander et al. (24) 2000 Biol Psychiatry	Double Blind RCT Cross-over design, 2 arms	Fluvoxam ine vs. Placebo	6/7	43.0 / 36.16	100% / 100%	Oral, fixed & cross-over	50mg	250m g	8-weeks	Yes	YES
16	Grant et al.(1) 2014 J Clin Psychiatry	Double Blind RCT Parallel design, 2 arms	NAC vs. Placebo	13/15	N/A	N/A	Oral, clinical judgement	1200 mg	3gr	12-weeks	No	NO
17	Hollander et al. (2) 2005 Am J Psychiatry	Double Blind RCT Parallel design, 2 arms	Lithium vs Placebo	18/22	40.0 / 47.7	50% / 35%	Oral, flexible	300m g sust. releas e	1200 mg sust. releas e	10-weeks	Yes	NO
18	Dannon et al.(25) 2011 Front Psych Res	Single-blinded (rater) RCT Parallel design, 2 arms	Baclofen vs Acampros ate	9/8	29.7 / 30.4	100% / 100%	Oral, flexible	10mg (B), 333m g (A)	50mg (B), 666m g (A)	6-month s	No	NO
19	Blanco et al. (26) 2002 Ann of Clin	Double Blind RCT Parallel	Fluvoxam ine vs. Placebo	15/17	42.3 / 41.9	67%/ 65%	Oral, titration	100m g	200m g	6-month s	Yes	NO

	Psychiatry	design, 2 arms									
20	Hollander et al. (27) 1992 Am J Psychiatry	Case report Cross-over	Clomipramine	1/1	31.0 / 31.0	0% / 0%	Oral, titration	25mg	150mg	10-weeks	No	NO
21	Saiz-Ruiz et al. (28) 2005 J Clin Psychiatry	Double Blind RCT Parallel design, 2 arms	Sertraline vs. Placebo	18/19	37.5 / 40.4	90% / 90%	Oral, flexible	50mg	150mg	24-weeks	Unclear	NO

†*active treatment*

Risk of Bias 2 assignments

Legend: *Risk of Bias 2 (Version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2)) (left); net graph plotted via CINeMA (right)*

Outcome Reporting Bias in Trials (ORBIT) assignments

Study ID (author, date of publication)	Review primary outcomes			Review secondary outcomes	Review harm outcomes
	PG-YBOCS	GSAS	CGI	QoL	Drop outs from side effects
Alho et al 2022	✳	✓	✳	✓	✓
De Brito et al 2017	✓	✓	✳	✓	✓
Kovanen et al 2016	✓	✳	✳	✓	✓
Berlin et al 2013	✓	✓	✳	✓	✓
Grant et al 2010	✓	✓	✳	✳	◯
Grant et al 2008	✓	✓	✓	✓	◯
Fong et al 2008	✳	✳	✓	✳	✓
Grant et al 2006	✓	✓	◯	◯	✓
Dannon et al 2005	✓	✳	✓	✳	✓
Grant et al 2003	✓	✓	✓	✓	✓
Kim et al 2001	✳	✓	◯	✳	✓
Hollander et al 2000	✓	✳	✓	✳	✓
McElroy et al 2008	✓	✳	✓	✳	✓
Kim et al 2002	✳	✓	✓	✳	✓

Legend : (✖) *is that the study did not report the outcome but it is not clear whether the outcome was measured or not. Full reporting (✓), partial reporting (◯) or not measured (✳)*

§S6 – Pairwise meta-analysis results

Gambling symptom severity

Tolerability

NOTE: Weights are from random effects analysis

Quality of life

Study ID	SMD (95% CI)	% Weight
Naloxone vs. Placebo		
Alho 2022	0.12 (-0.23, 0.47)	100.00
Subtotal (I-squared = .%, p = .)	0.12 (-0.23, 0.47)	100.00
.		
Topiramate vs. Placebo		
Berlin 2013	-0.34 (-0.95, 0.27)	53.13
de Brito 2017	-0.54 (-1.19, 0.10)	46.87
Subtotal (I-squared = 0.0%, p = 0.645)	-0.43 (-0.88, 0.01)	100.00
.		
Naltrexone vs. Placebo		
Grant 2008	-0.53 (-1.06, -0.01)	36.19
Kovanen 2016	-0.47 (-0.86, -0.07)	63.81
Subtotal (I-squared = 0.0%, p = 0.846)	-0.49 (-0.81, -0.18)	100.00
.		
Bupropion vs. Placebo		
Black 2007	0.07 (-0.62, 0.75)	100.00
Subtotal (I-squared = .%, p = .)	0.07 (-0.62, 0.75)	100.00
.		
Nalmefene vs. Placebo		
Grant 2006	-0.36 (-0.72, -0.01)	100.00
Subtotal (I-squared = .%, p = .)	-0.36 (-0.72, -0.01)	100.00
.		
Paroxetine vs. Placebo		
Grant 2003	-0.09 (-0.56, 0.37)	100.00
Subtotal (I-squared = .%, p = .)	-0.09 (-0.56, 0.37)	100.00

NOTE: Weights are from random effects analysis

-1.19   0   1.19

PG-YBOCS only (gambling severity secondary analysis)

GSAS only (gambling severity secondary analysis)

Study ID	MD (95% CI)	% Weight
Naloxone vs. Placebo		
Alho 2022	1.38 (-1.90, 4.67)	100.00
Subtotal (I-squared = .%, p = .)	1.38 (-1.90, 4.67)	100.00
Topiramate vs. Placebo		
Berlin 2013	-3.06 (-9.34, 3.22)	50.05
de Brito 2017	-5.10 (-11.39, 1.19)	49.95
Subtotal (I-squared = 0.0%, p = 0.653)	-4.08 (-8.52, 0.37)	100.00
Naltrexone vs. Placebo		
Grant 2008	-5.50 (-10.54, -0.46)	32.47
Kim 2001	-5.00 (-8.49, -1.51)	67.53
Subtotal (I-squared = 0.0%, p = 0.873)	-5.16 (-8.03, -2.29)	100.00
Bupropion vs. Placebo		
Black 2007	0.80 (-4.73, 6.33)	100.00
Subtotal (I-squared = .%, p = .)	0.80 (-4.73, 6.33)	100.00
Nalmefene vs. Placebo		
Grant 2006	-5.68 (-9.84, -1.52)	100.00
Subtotal (I-squared = .%, p = .)	-5.68 (-9.84, -1.52)	100.00
Paroxetine vs. Placebo		
Grant 2003	-1.10 (-6.35, 4.15)	60.21
Kim 2002	-9.00 (-17.75, -0.25)	39.79
Subtotal (I-squared = 56.6%, p = 0.129)	-4.24 (-11.82, 3.34)	100.00

NOTE: Weights are from random effects analysis

-17.7   0   17.7

CGI-I only (gambling severity secondary analysis)

Study ID	MD (95% CI)	% Weight
Naltrexone vs. Placebo		
Grant 2008	-0.60 (-1.35, 0.15)	100.00
Subtotal (I-squared = .%, p = .)	-0.60 (-1.35, 0.15)	100.00
Olanzapine vs. Placebo		
Fong 2008	-0.34 (-0.90, 0.22)	100.00
Subtotal (I-squared = .%, p = .)	-0.34 (-0.90, 0.22)	100.00
Bupropion vs. Placebo		
Black 2007	0.12 (-0.66, 0.91)	100.00
Subtotal (I-squared = .%, p = .)	0.12 (-0.66, 0.91)	100.00
Bupropion vs. Naltrexone		
Dannon 2005	-0.20 (-1.80, 1.40)	100.00
Subtotal (I-squared = .%, p = .)	-0.20 (-1.80, 1.40)	100.00
Fluvoxamine vs. Placebo		
Hollander 2000	-0.30 (-1.30, 0.70)	100.00
Subtotal (I-squared = .%, p = .)	-0.30 (-1.30, 0.70)	100.00

NOTE: Weights are from random effects analysis

§S7 – Results from NMA for each gambling severity scale

PG-YBOCS only (gambling severity sensitivity analysis)

Legend: *Node size by number of studies; Node colour by RoB2; Edge width by sample size*

topiramate							
-2.48 (-5.79,0.84)	placebo						
-3.98 (-9.32,1.37)	-1.50 (-5.70,2.70)	paroxetine					
-2.08 (-7.31,3.16)	0.40 (-3.65,4.45)	1.90 (-3.94,7.74)	olanzapine				
-0.11 (-4.21,3.99)	2.37 (-0.05,4.78)	3.87 (-0.98,8.71)	1.97 (-2.75,6.68)	naltrexone			
0.19 (-3.64,4.03)	**2.67 (0.72,4.62)**	4.17 (-0.46,8.80)	2.27 (-2.23,6.77)	0.30 (-2.85,3.45)	nalmefene		
-1.06 (-11.35,9.24)	1.42 (-8.33,11.17)	2.92 (-7.69,13.53)	1.02 (-9.54,11.58)	-0.95 (-10.99,9.10)	-1.25 (-11.19,8.69)	fluvoxamine	
-0.59 (-5.21,4.03)	1.89 (-1.34,5.11)	3.39 (-1.90,8.68)	1.49 (-3.69,6.66)	-0.48 (-3.34,2.38)	-0.78 (-4.72,3.15)	0.47 (-9.80,10.73)	bupropion

GSAS only (gambling severity sensitivity analysis)

Legend: *Node size by number of studies; Node colour by RoB2; Edge width by sample size*

placebo						
5.16 (2.29,8.03)	naltrexone					
-1.38 (-4.67,1.90)	**-6.55 (-10.91,-2.19)**	naloxone				
4.08 (-0.37,8.52)	-1.08 (-6.37,4.21)	5.46 (-0.06,10.99)	topiramate			
3.19 (-1.31,7.69)	-1.97 (-7.31,3.37)	4.58 (-1.00,10.15)	-0.89 (-7.21,5.44)	paroxetine		
5.68 (1.52,9.84)	0.52 (-4.54,5.57)	**7.07 (1.76,12.37)**	1.60 (-4.49,7.69)	2.49 (-3.64,8.62)	nalmefene	
-0.80 (-6.33,4.73)	-5.96 (-12.19,0.27)	0.58 (-5.85,7.02)	-4.88 (-11.98,2.22)	-3.99 (-11.12,3.14)	-6.48 (-13.40,0.44)	bupropion

CGI-I only (gambling severity sensitivity analysis)

Legend: *Node size by number of studies; Node colour by RoB2; Edge width by sample size*

placebo				
0.34 (-0.22,0.90)	olanzapine			
0.46 (-0.23,1.15)	0.12 (-0.77,1.01)	naltrexone		
0.30 (-0.70,1.30)	-0.04 (-1.19,1.11)	-0.16 (-1.38,1.06)	fluvoxamine	
0.03 (-0.69,0.75)	-0.31 (-1.22,0.60)	-0.43 (-1.33,0.47)	-0.27 (-1.50,0.96)	bupropion

§S8 – Heterogeneity measures within NMA and results from incoherence assessment for all outcomes

Gambling symptom severity

Standard deviation heterogeneity: tau= 0.28

Loop-specific approach

Node-splitting approach

Side	Direct Coef.	Std. Err.	Indirect Coef.	Std. Err.	Difference Coef.	Std. Err.	P>|z|	tau
1 2	-.4893801	.2256403	.0797935	.6370658	-.5691736	.6758449	0.400	.2933344
1 3	.	.	.	.	.	.	.	.
1 4	.	.	.	.	.	.	.	.
1 5	.0013682	.4563634	-.5678038	.4985092	.569172	.6758542	0.400	.2933347
1 6	.	.	.	.	.	.	.	.
1 7	.	.	.	.	.	.	.	.
1 8	.	.	.	.	.	.	.	.
1 9	.	.	.	.	.	.	.	.
2 5	-.0784294	.4445205	.4907499	.5090978	-.5691793	.6758537	0.400	.2933348

Design-by-treatment approach

chi2(1) =   0.71; Prob > chi2 =   0.3997

Tolerability

Standard deviation heterogeneity

Tau= 2.918e-09

Loop-specific approach

Node-splitting approach

Side	Direct		Indirect		Difference			tau
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.	P>|z|	
1 2	1.798493	1.110488	2.677225	1.72214	-.8787317	2.049134	0.668	7.70e-10
1 3	.	.	.	.	.	.	.	.
1 4	2.273123	1.548141	1.392549	1.342855	.8805737	2.04939	0.667	9.29e-10
1 5	.	.	.	.	.	.	.	.
1 6	.	.	.	.	.	.	.	.
1 7	.	.	.	.	.	.	.	.
1 8	.	.	.	.	.	.	.	.
2 4	-.4054479	.7553228	.4743899	1.905218	-.8798379	2.049478	0.668	7.88e-10

Design-by-treatment approach

chi2(1) =   0.18   Prob > chi2 =   0.6675

PG-YBOCS only (gambling severity sensitivity analysis)

Standard deviation heterogeneity

Tau= 0.37

Loop-specific Approach

Node-splitting approach

Side	Direct		Indirect		Difference			tau
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.	P>|z|	
1 2	-2.924889	1.351395	.4096319	3.008528	-3.334521	3.298106	0.312	.3851565
1 3	.	.	.	.	.	.	.	.
1 4	.01	2.487543	-3.324334	2.167351	3.334334	3.299285	0.312	.3852022
1 5	.	.	.	.	.	.	.	.
1 6	.	.	.	.	.	.	.	.
1 7	.	.	.	.	.	.	.	.
1 8	.	.	.	.	.	.	.	.
2 4	-.4001712	1.694514	2.935165	2.83086	-3.335336	3.299175	0.312	.3852742

Design-by-treatment approach

chi2(1) =   1.02; Prob > chi2 =   0.3122

CGI-I only (gambling severity sensitivity analysis)

Standard deviation heterogeneity

Tau= 2.737e-07

Loop-specific Approach

Node-splitting approach

Side	Direct		Indirect		Difference			tau
	Coef.	Std. Err.	Coef.	Std. Err.	Coef.	Std. Err.	P>|z|	
1 2	-.5999958	.3846291	.3219379	.9103756	-.9219337	.9882861	0.351	.002588
1 3	.	.	.	.	.	.	.	.
1 4	.1219881	.4006154	-.7999494	.9035741	.9219375	.9884224	0.351	.0069315
1 5	.	.	.	.	.	.	.	.
2 4	-.2000055	.8175473	.7220003	.5553066	-.9220057	.9883084	0.351	.0009115

Design-by-treatment approach

$Chi^2(1) = 0.87$; $Prob > chi^2 = 0.3509$

§S9 - Treatment rankings from main NMA, treatment effect, tolerability and quality of life

Main Treatment effect				Tolerability				Quality of life			
Treatment	SUCRA	PrBest	MeanRank	Treatment	SUCRA	PrBest	MeanRank	Treatment	SUCRA	PrBest	MeanRank
Nalmefene	94.2	69.0	1.5	Placebo	90.9	50.4	1.6	Naltrexone	85.4	43.3	1.9
Naltrexone	67.6	4.1	3.6	Olanzapine	63.4	11.2	3.6	Topiramate	78.0	32.6	2.3
Topiramate	57.6	4.7	4.4	Topiramate	57.3	12.0	4.0	Nalmefene	72.2	17.3	2.7
Bupropion	50.4	4.6	5.0	Paroxetine	50.7	5.3	4.4	Paroxetine	41.2	2.9	4.5
Olanzapine	49.6	3.5	5.0	Bupropion	36.7	2.5	5.4	Placebo	29.1	0.0	5.3
Fluvoxamine	44.0	12.6	5.5	Fluvoxamine	47.3	18.1	4.7	Bupropion	27.5	3.8	5.3
Paroxetine	43.0	1.4	5.6	Nalmefene	27.1	0.0	6.1	Naloxone	16.6	0.0	6.0
Placebo	24.4	0.0	7.0	Naltrexone	26.5	0.5	6.1	Olanzapine	NA	NA	NA
Naloxone	19.2	0.2	7.5	Naloxone	NA	NA	NA	Fluvoxamine	NA	NA	NA

Legend: *Treatment rankings from the main network meta-analysis. SUCRA = surface under the cumulative ranking curve; PrBest = Probability of treatment to produce the best effect out of all comparators (Note:*

PrBest is biased towards treatments with high uncertainty of evidence); Mean Rank = Probabilistic ranking

metric, i.e. the probability that a treatment achieves a specific rank (29).

§S10 CINeMA full reports

Gambling symptoms severity

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Bupropion:Naltrexone	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Placebo	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Fluvoxamine:Placebo	1	Major concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Nalmefene:Placebo	2	Some concerns	Low risk	No concerns	No concerns	Some concerns	No concerns	High
Naloxone:Placebo	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Naltrexone:Placebo	3	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Moderate
Olanzapine:Placebo	2	Major concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Very low
Paroxetine:Placebo	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Placebo:Topiramate	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Fluvoxamine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Nalmefene	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Naloxone	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Olanzapine	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low
Bupropion:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Fluvoxamine:Nalmefene	0	Some	Low risk	No concerns	Major	No concerns	No concerns	Moderate

PHARMACOLOGICAL MANAGEMENT OF GAMBLING DISORDER: A NETWORK META-ANALYSIS

Comparison								
Fluvoxamine:Naloxone	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Fluvoxamine:Naltrexone	0	Major concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Very low
Fluvoxamine:Olanzapine	0	Major concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Very low
Fluvoxamine:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Fluvoxamine:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Nalmefene:Naloxone	0	Some concerns	Low risk	No concerns	No concerns	Major concerns	No concerns	Moderate
Nalmefene:Naltrexone	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low
Nalmefene:Olanzapine	0	Some concerns	Some concerns	No concerns	Some concerns	Some concerns	No concerns	Moderate
Nalmefene:Paroxetine	0	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Moderate
Nalmefene:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Naloxone:Naltrexone	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low
Naloxone:Olanzapine	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low
Naloxone:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Naloxone:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Naltrexone:Olanzapine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Naltrexone:Paroxetine	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low
Naltrexone:Topiramate	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low
Olanzapine:Paroxetine	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low

Olanzapine:Topiramate	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	No concerns	Low
Paroxetine:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate

Tolerability

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Bupropion:Naltrexone	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Placebo	1	Some concerns	Low risk	No concerns	Some concerns	Some concerns	No concerns	Moderate
Fluvoxamine:Placebo	1	Major concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Nalmefene:Placebo	1	Some concerns	Low risk	No concerns	No concerns	No concerns	No concerns	High
Naltrexone:Placebo	2	Some concerns	Low risk	No concerns	No concerns	Major concerns	No concerns	Moderate
Olanzapine:Placebo	2	Major concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Paroxetine:Placebo	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Placebo:Topiramate	2	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Fluvoxamine	0	Major concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Bupropion:Nalmefene	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Olanzapine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Bupropion:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Fluvoxamine:Nalmefene	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Fluvoxamine:Naltrexone	0	Major concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Fluvoxamine:Olanzapine	0	Major concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Fluvoxamine:Paroxetine	0	Some	Low risk	No concerns	Major	No concerns	No concerns	Moderate

Comparison								
		concerns			concerns			
Fluvoxamine:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Nalmefene:Naltrexone	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Nalmefene:Olanzapine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Nalmefene:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Nalmefene:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Naltrexone:Olanzapine	0	Major concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Low
Naltrexone:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Naltrexone:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Olanzapine:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Olanzapine:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate
Paroxetine:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	No concerns	Moderate

Quality of Life

Comparison	Number of studies	Within-study bias	Reporting bias	Indirectness	Imprecision	Heterogeneity	Incoherence	Confidence rating
Bupropion:Placebo	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Nalmefene:Placebo	1	Some concerns	Some concerns	No concerns	No concerns	Major concerns	Some concerns	Low
Naloxone:Placebo	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Naltrexone:Placebo	2	Major concerns	Low risk	No concerns	No concerns	Major concerns	Some concerns	Very low
Paroxetine:Placebo	1	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Placebo:Topiramate	2	Some concerns	Low risk	No concerns	Some concerns	Some concerns	Some concerns	Moderate
Bupropion:Nalmefene	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Bupropion:Naloxone	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Bupropion:Naltrexone	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Bupropion:Paroxetine	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Bupropion:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Nalmefene:Naloxone	0	Some concerns	Some concerns	No concerns	Some concerns	Some concerns	Some concerns	Low
Nalmefene:Naltrexone	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	Some concerns	Low
Nalmefene:Paroxetine	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	Some concerns	Low
Nalmefene:Topiramate	0	Some concerns	Some concerns	No concerns	Major concerns	No concerns	Some concerns	Low
Naloxone:Naltrexone	0	Some concerns	Low risk	No concerns	No concerns	Major concerns	Some concerns	Low
Naloxone:Paroxetine	0	Some	Low risk	No concerns	Major	No concerns	Some	Low

		concerns			concerns		concerns	
Naloxone:Topiramate	0	Some concerns	Low risk	No concerns	Some concerns	Some concerns	Some concerns	Moderate
Naltrexone:Paroxetine	0	Some concerns	Low risk	No concerns	Some concerns	Some concerns	Some concerns	Moderate
Naltrexone:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low
Paroxetine:Topiramate	0	Some concerns	Low risk	No concerns	Major concerns	No concerns	Some concerns	Low

Supplemental References

1.   Grant JE, Odlaug BL, Chamberlain SR, Potenza MN, Schreiber LRN, Donahue CB, et al. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry [Internet]. 2014 [cited 2022 Mar 25];75(1):39–45. Available from: https://pubmed.ncbi.nlm.nih.gov/24345329/

2.   Hollander E, Pallanti S, Allen A, Sood E, Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry [Internet]. 2005 Jan [cited 2023 Aug 5];162(1):137–45. Available from: https://pubmed.ncbi.nlm.nih.gov/15625212/

3.   The Cochrane Collaboration. Cochrane Handbook, 16.9.3 studies with no events [Internet]. Available from: https://handbook-5-1.cochrane.org/chapter_16/16_9_3_studies_with_no_events.htm#:~:text=The   standard   practice   in meta,of the relative treatment effect

4.   The Cochrane Collaboration. Cochrane Handbook, 7.7 Extracting study results and converting to the desired   format   [Internet].   Available   from: https://handbook-5-1.cochrane.org/chapter_7/7_7_extracting_study_results_and_converting_to_the_desired.htm

5.   Alho H, Mäkelä N, Isotalo J, Toivonen L, Ollikainen J, Castrén S. Intranasal as needed naloxone in the treatment of gambling disorder: A randomised controlled trial. Addict Behav [Internet]. 2022 Feb 1 [cited 2023 Jun 25];125. Available from: https://pubmed.ncbi.nlm.nih.gov/34634640/

6.   Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med [Internet]. 2015 Jun 2 [cited 2023 Oct 6];162(11):777–84. Available from: https://pubmed.ncbi.nlm.nih.gov/26030634/

7.   Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Giovane C Del, Egger M, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLOS Med

[Internet]. 2020 Apr 2 [cited 2023 Aug 9];17(4):e1003082. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003082

8.   Chiocchia V, Nikolakopoulou A, Higgins JPT, Page MJ, Papakonstantinou T, Cipriani A, et al. ROB-MEN: a tool to assess risk of bias due to missing evidence in network meta-analysis. BMC Med [Internet]. 2021 Dec 1 [cited 2023 Jun 25];19(1):1–13. Available from: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02166-3

9.   ORBIT. Outcome Reporting Bias in Trials [Internet]. 2023 [cited 2023 Jun 25]. Available from: https://outcome-reporting-bias.org/About

10.   Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev [Internet]. 2020 Mar 1 [cited 2023 Aug 9];16(1):e1080. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/cl2.1080

11.   de Brito AMC, de Almeida Pinto MG, Bronstein G, Carneiro E, Faertes D, Fukugawa V, et al. Topiramate Combined with Cognitive Restructuring for the Treatment of Gambling Disorder: A Two-Center, Randomized, Double-Blind Clinical Trial. J Gambl Stud [Internet]. 2017 Mar 1 [cited 2023 Jun 25];33(1):249–63. Available from: https://link.springer.com/article/10.1007/s10899-016-9620-z

12.   Kovanen L, Basnet S, Castrén S, Pankakoski M, Saarikoski ST, Partonen T, et al. A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling. Eur Addict Res [Internet]. 2016 Jan 1 [cited 2023 May 30];22(2):70–9. Available from: https://pubmed.ncbi.nlm.nih.gov/26339899/

13.   McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry [Internet]. 2008 [cited 2023 Jun 25];69(3):433–40. Available from: https://pubmed.ncbi.nlm.nih.gov/18251624/

14.   Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, et al. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry [Internet]. 2013 Mar

[cited 2023 Jun 25];14(2):121–8. Available from: https://pubmed.ncbi.nlm.nih.gov/21486110/

15.   Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry [Internet]. 2010 Oct [cited 2022 May 25];197(4):330–1. Available from: https://pubmed.ncbi.nlm.nih.gov/20884959/

16.   Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl). 2008 Nov;200(4):521–7.

17.   Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav [Internet].   2008   May   [cited   2023   Jun   25];89(3):298–303.   Available   from: https://pubmed.ncbi.nlm.nih.gov/18261787/

18.   Black DW, Arndt S, Coryell WH, Argo T, Forbush KT, Shaw MC, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study. J Clin Psychopharmacol [Internet]. 2007 Apr [cited 2023 Aug 5];27(2):143–50. Available from: https://pubmed.ncbi.nlm.nih.gov/17414236/

19.   Grant JE, Potenza MN, Hollander E, Cynningham-Williams R, Nurminen T, Smits G, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry [Internet]. 2006 Feb [cited 2022 May 25];163(2):303–12. Available from: https://pubmed.ncbi.nlm.nih.gov/16449486/

20.   Dannon PN, Lowengrub K, Musin E, Gonopolski Y, Kotler M. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol [Internet]. 2005 Dec [cited 2023 May 30];25(6):593–6. Available from: https://pubmed.ncbi.nlm.nih.gov/16282845/

21.   Kim SW, Grant JE, Adson DE, Zaninelli R. A Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Paroxetine in the Treatment of Pathological Gambling. J Clin Psychiatry [Internet]. 2002 Jun   18   [cited   2023   Jun   25];63(6):4776.   Available   from:

https://www.psychiatrist.com/jcp/ocd/pathological-gambling/double-blind-placebo-controlled-study-efficacy-safety-paroxetine-pathological-gambling

22.   Grant JE, Kim SW, Potenza MN, Blanco C, Ibanez A, Stevens L, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol [Internet]. 2003 [cited 2023 Jun 25];18(4):243–9. Available from: https://pubmed.ncbi.nlm.nih.gov/12817159/

23.   Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry [Internet]. 2001 Jun 1 [cited 2022 May 31];49(11):914–21. Available from: https://pubmed.ncbi.nlm.nih.gov/11377409/

24.   Hollander E, Decaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry [Internet]. 2000 May 1 [cited 2023 Jun 25];47(9):813–7. Available from: https://pubmed.ncbi.nlm.nih.gov/10812040/

25.   Dannon PN, Rosenberg O, Schoenfeld N, Kotler M. Acamprosate and baclofen were not effective in the treatment of pathological gambling: Preliminary blind rater comparison study. Front Psychiatry. 2011 Jun 6;2(JUN):10985.

26.   Blanco C, Petkova E, Ibáñez A, Sáiz-Ruiz J. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry [Internet]. 2002 [cited 2023 Aug 5];14(1):9–15. Available from: https://pubmed.ncbi.nlm.nih.gov/12046642/

27.   Hollander E, Frenkel M, Decaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine. Am J Psychiatry [Internet]. 1992 [cited 2023 Aug 5];149(5):710–1. Available from: https://pubmed.ncbi.nlm.nih.gov/1575267/

28.   Saiz-Ruiz J, Blanco C, Ibáñez A, Masramon X, Gómez MM, Madrigal M, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry [Internet]. 2005 [cited 2023 Aug 5];66(1):28–33. Available from: https://pubmed.ncbi.nlm.nih.gov/15669885/

29.   Chiocchia V, Nikolakopoulou A, Papakonstantinou T, Egger M, Salanti G. Agreement between

ranking metrics in network meta-analysis: an empirical study. BMJ Open [Internet]. 2020 Aug 1 [cited 2023 Jun 24];10(8):e037744. Available from: https://bmjopen.bmj.com/content/10/8/e037744

§S11 Example of STATA code for network meta-analysis

Network meta-analysis (NMA) is a statistical technique used to combine direct and indirect evidence from multiple studies that compare multiple treatments. Here's a simplified example of how you might perform a network meta-analysis using Stata. Please note that you would need to adapt this code to your specific dataset and research question.

ssc install netmeta #Load the required packages for network meta-analysis

use "your_dataset.dta", clear #* Load your dataset (replace "your_dataset.dta" with your actual dataset file)

netmeta id study_id treatment outcome effect se_lower se_upper #* Specify the variables for the analysis

netmegen id study_id treatment outcome effect se_lower se_upper, graph #* Perform the network meta-analysis

netmeprev random #* Run the network meta-analysis model (you might need to adjust the model specification)

netmesum #* Summarize the results

netmetaforest #* Generate forest plots

netmetaleague # * Generate league tables

netmetasucra # * Generate surface under the cumulative ranking (SUCRA) plots

netmetarankogram #* Generate rankograms

netmetasave "results_output.dta" #* Save the results